Autosomal Recessive Dopa-Responsive Dystonia

Genetic MONDO:0011551 Pathograph 47 Show in embeddings browser Dopa-responsive dystonia Inborn Error of Metabolism Movement Disorder

TH-deficient dopa-responsive dystonia is a very rare autosomal recessive neurometabolic disorder caused by biallelic pathogenic variants in TH. Reduced tyrosine hydroxylase activity limits the rate-limiting conversion of tyrosine to L-dopa and depletes dopamine and other catecholamines in the central nervous system. Clinical expression is continuous, ranging from childhood-onset, levodopa-responsive dystonia to infantile parkinsonism with motor delay and severe early encephalopathy with variable levodopa response.

Ask OpenScientist

Ask a research question about Autosomal Recessive Dopa-Responsive Dystonia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal recessive inheritance HP:0000007

Autosomal recessive inheritance

Show evidence (2 references)

ORPHA:101150 SUPPORT Other

"Autosomal recessive"

Orphanet records autosomal recessive inheritance.

PMID:20301610 SUPPORT Other

"TH deficiency is inherited in an autosomal recessive manner."

GeneReviews states autosomal recessive inheritance.

◆

Subtypes

TH-deficient dopa-responsive dystonia

Mild TH deficiency with childhood lower-limb dystonia, gait disturbance, possible diurnal fluctuation, and complete levodopa responsiveness.

Show evidence (1 reference)

PMID:20301610 SUPPORT Other

"In individuals with TH-deficient dopa-responsive dystonia (DYT5b, DYT-TH), onset is between age 12 months and 12 years; initial symptoms are typically lower-limb dystonia and/or difficulty in walking."

GeneReviews defines the mild TH-deficient DRD phenotype.

TH-deficient infantile parkinsonism with motor delay

Severe TH deficiency presenting in infancy with motor delay, hypotonia, and parkinsonian signs including hypokinesia, rigidity, and tremor.

Show evidence (1 reference)

PMID:20301610 SUPPORT Other

"In most individuals with TH-deficient infantile parkinsonism with motor delay, onset is between age three and 12 months."

GeneReviews defines the infantile parkinsonism phenotype.

TH-deficient progressive infantile encephalopathy

Very severe early-onset TH deficiency with marked motor delay, hypotonia, hyperreflexia, oculogyric crises, ptosis, intellectual disability, lethargy, irritability, sweating, and drooling.

Show evidence (1 reference)

PMID:20301610 SUPPORT Other

"In individuals with TH-deficient progressive infantile encephalopathy, onset is before age three to six months."

GeneReviews defines the very severe early-onset phenotype.

Discussions and Knowledge Gaps

Which genotype, biochemical, and clinical markers should guide starting dose, titration rate, and adjunctive therapy across the TH-deficiency severity spectrum?

KNOWLEDGE GAP OPEN gap_thd_genotype_guided_levodopa_dosing

Attached to

genetic#TH biallelic pathogenic variants treatments#Severity-adapted levodopa with a decarboxylase inhibitor

The largest pediatric cohort associates second-allele variant class with dose requirements among p.R233H carriers, but it is single-center and single-ethnicity. The consensus guideline notes that available evidence is limited, while severe patients remain vulnerable to dyskinesia.

Show evidence (2 references)

PMID:41121981 SUPPORT Human Clinical

"Variant type-particularly R233H/nonsense versus R233H/missense significantly influences dose requirements, underscoring the value of genotype-guided, dynamic levodopa titration to optimize long-term outcomes."

The cohort provides a testable genotype-dose association.

PMID:41215497 SUPPORT Other

"Based on the limited evidence, practical recommendations have been developed to support clinical diagnosis, laboratory testing, neuroimaging, medical treatment, and non-medical interventions."

The guideline explicitly characterizes the evidence base as limited.

Does treatment before symptomatic neurodevelopmental injury improve cognition and motor-network development in severe TH deficiency?

KNOWLEDGE GAP OPEN gap_thd_developmental_treatment_window

Attached to

pathophysiology#Infantile Catecholamine Deficiency Encephalopathy experimental_models#Patient-derived THD iPSC dopaminergic neurons clinical_trials#NCT03655223 clinical_trials#NCT05687474

Patient-derived neurons suggest that precursor-stage levodopa can prevent severe-cell defects even when mature neurons respond poorly, and clinical consensus favors early diagnosis. The two registry studies screen newborns, but no disease-specific prospective early-treatment trial was identified.

Show evidence (2 references)

PMID:36740977 SUPPORT In Vitro

"Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD."

The cellular model motivates prospective testing of treatment timing.

PMID:41215497 SUPPORT Other

"Clinical experience suggests that early diagnosis and treatment initiation may improve the outcome."

Clinical consensus supports early treatment while acknowledging limited evidence.

Which TH genotypes can be stabilized by BH4 in vivo, and can clinically achievable exposure add benefit to levodopa without worsening adverse effects?

KNOWLEDGE GAP OPEN gap_bh4_precision_rescue_translation

Attached to

pathophysiology#Biallelic TH Loss of Function experimental_models#BH4 stabilization assay in THD patient-derived neurons animal_models#Th-p.R203H knock-in mouse corresponding to human TH p.R202H/p.R233H disease nomenclature

BH4 rescued TH abundance, dopamine, and motor phenotypes in selected patient-derived neurons and a knock-in mouse. The effect was genotype-dependent and no TH-deficiency-specific human interventional trial was identified, so BH4 remains preclinical for this indication.

Show evidence (1 reference)

PMID:38196161 SUPPORT In Vitro

"These findings highlight the therapeutic potential of BH4 as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management."

The study itself frames BH4 as variant-specific therapeutic potential.

Which care pathways and communication practices reduce diagnostic delay and family psychological burden across health systems?

KNOWLEDGE GAP OPEN gap_thd_family_diagnostic_burden

Attached to

diagnosis#Molecular genetic testing external_assertions#iNTD longitudinal patient registry

The first focused caregiver study involved only five Serbian parents and found uncertainty, communication challenges, and emotional strain. Multinational registry work is needed to test generalizability and identify modifiable care-system factors.

Show evidence (1 reference)

PMID:42141694 SUPPORT Human Clinical

"Given the preliminary nature of this research and its geographic focus on Serbia, the findings are exploratory and may not generalize to other populations."

The qualitative study explicitly identifies its generalizability limit.

⚙

Pathophysiology

Biallelic TH Loss of Function

Biallelic pathogenic variants reduce TH catalytic activity, abundance, or stability. This impairs the tetrahydrobiopterin-dependent conversion of tyrosine to L-dopa, the rate-limiting step of catecholamine biosynthesis.

TH hgnc:11782

catecholamine biosynthetic process GO:0042423 ↓ DECREASED dopamine biosynthetic process from tyrosine GO:0006585 ↓ DECREASED

tyrosine 3-monooxygenase activity GO:0004511 ↓ DECREASED

Experimental models

Patient-derived THD iPSC dopaminergic neurons IPSC DERIVED MODEL Patient neurons model reduced TH abundance caused by biallelic disease alleles.

BH4 stabilization assay in THD patient-derived neurons IPSC DERIVED MODEL BH4 tests rescue of variant-associated TH instability.

Downstream

Cerebral Catecholamine Deficiency Reduced TH function limits CNS dopamine, norepinephrine, and epinephrine synthesis.

Show evidence (5 references)

PMID:9703425 SUPPORT Human Clinical

"This report concerns one new mutation in the tyrosine hydroxylase (TH) gene in three patients originating from three unrelated Dutch families with autosomal recessive L-DOPA-responsive dystonia (DRD)."

Human mutation evidence supports TH as a causative gene for autosomal recessive L-DOPA-responsive dystonia.

PMID:20301610 SUPPORT Other

"The diagnosis of TH deficiency is established in a proband by identification of biallelic pathogenic variants in TH by molecular genetic testing."

GeneReviews supports biallelic TH pathogenic variants as the diagnostic molecular lesion.

PMID:34834538 SUPPORT Other

"TH is a key enzyme that catalyzes the rate-limiting step in catecholamine biosynthesis, and THD patients often present with complex and variable phenotypes, which results in frequent misdiagnosis and lack of appropriate treatment."

Expert review supports the biochemical role of TH and links THD to the clinical spectrum.

+ 2 more references

Cerebral Catecholamine Deficiency

Reduced TH flux lowers dopamine and other catecholamines in the CNS. Dopamine depletion is central to motor disease, while broader catecholamine loss contributes to autonomic and severe neurodevelopmental manifestations.

dopaminergic neuron CL:0000700

dopamine biosynthetic process GO:0042416 ↓ DECREASED

basal ganglion UBERON:0002420

Experimental models

Patient-derived THD iPSC dopaminergic neurons IPSC DERIVED MODEL Reduced dopamine metabolites model the central biochemical defect.

Downstream

Dopamine-Responsive Motor Circuit Dysfunction Dopamine depletion disrupts basal-ganglia motor control.

Infantile Catecholamine Deficiency Encephalopathy Severe early catecholamine deficiency disrupts motor and neurodevelopment.

Autonomic Catecholamine Dysfunction Norepinephrine and epinephrine deficiency contributes to autonomic manifestations.

Stress-Triggered Neurologic Decompensation Infection or vaccination can precipitate episodic regression in a subset of patients.

Striatal Inhibitory Circuit Remodeling A knock-in model suggests circuit imbalance and compensatory plasticity.

Decreased CSF Homovanillic Acid Reduced dopamine synthesis lowers its CSF metabolite HVA.

Show evidence (3 references)

PMID:34834538 SUPPORT Other

"Dopa-responsive dystonia (DRD) is a rare movement disorder associated with defective dopamine synthesis."

Expert review links DRD to defective dopamine synthesis.

PMID:20301610 SUPPORT Other

"Affected infants demonstrate truncal hypotonia and parkinsonian symptoms and signs (hypokinesia, rigidity of extremities, and/or tremor)."

GeneReviews links TH deficiency to parkinsonian motor signs downstream of dopamine synthesis impairment.

PMID:41215497 SUPPORT Other

"Tyrosine hydroxylase (TH) catalyses the rate-limiting step in dopamine biosynthesis."

The consensus supports the central biochemical defect.

Dopamine-Responsive Motor Circuit Dysfunction

Dopamine depletion in motor circuits produces dystonia, parkinsonism, hypokinesia, rigidity, tremor, ataxic gait, and oculogyric crises. The strong response of the mild phenotype to levodopa supports this functional rather than degenerative motor-circuit mechanism.

basal ganglion UBERON:0002420

Downstream

Limb Dystonia

Focal Dystonia

Generalized Dystonia

Parkinsonism

Bradykinesia

Hypokinesia

Rigidity

Extrapyramidal Motor Dysfunction

Postural Tremor

Myoclonus

Ataxia

Gait Ataxia

Oculogyric Crisis

Show evidence (1 reference)

PMID:41121981 SUPPORT Human Clinical

"Movement disorders were present in 96.1% of cases, with developmental delay observed in 88.2%, and autonomic symptoms in 51.0%."

The pediatric cohort documents the near-universal movement-disorder burden.

Infantile Catecholamine Deficiency Encephalopathy

Severe early-onset TH deficiency can extend beyond focal dystonia to infantile parkinsonism and progressive infantile encephalopathy, with motor delay, hypotonia, ptosis, hyperreflexia, lethargy, irritability, excessive sweating, and drooling.

Downstream

Motor Delay

Hypotonia

Axial Hypotonia

Ptosis

Brisk Reflexes

Lower Limb Hyperreflexia

Babinski Sign

Mild Intellectual Disability

Delayed Speech and Language Development

Lethargy

Irritability

Feeding Difficulties

Pes Cavus

Talipes Equinovarus

Progressive Encephalopathy

Show evidence (2 references)

PMID:20301610 SUPPORT Other

"In individuals with TH-deficient progressive infantile encephalopathy, onset is before age three to six months."

GeneReviews supports very early onset in the severe phenotype.

PMID:20301610 SUPPORT Other

"Affected individuals have marked delay in motor development, truncal hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual disability, and paroxysmal periods of lethargy (with increased sweating and drooling)..."

GeneReviews supports the infantile encephalopathy clinical consequences.

Autonomic Catecholamine Dysfunction

Central catecholamine deficiency can produce sweating, drooling, and gastrointestinal dysmotility, especially in severe infantile disease.

Downstream

Excessive Salivation

Night Sweats

Constipation

Show evidence (1 reference)

PMID:41121981 SUPPORT Human Clinical

"Movement disorders were present in 96.1% of cases, with developmental delay observed in 88.2%, and autonomic symptoms in 51.0%."

The largest pediatric cohort documents autonomic manifestations in about half.

Stress-Triggered Neurologic Decompensation

A subset of patients can develop episodic lethargy, worsened tremor, language and motor regression, and axial hypotonia after infection or vaccination, with recovery over weeks and prevention of recurrence after levodopa/carbidopa in the reported cases.

Downstream

Lethargy

Axial Hypotonia

Show evidence (1 reference)

PMID:36101825 SUPPORT Human Clinical

"Literature review revealed four other THD patients who had a total of seven episodes of marked hypotonia and motor regression following infections, occurring between ages 12 months and 6 years."

The report extends the episodic presentation beyond one patient.

Striatal Inhibitory Circuit Remodeling

In the Th-p.R203H knock-in mouse, regionally reduced TH without reduced Th transcript or dopaminergic neuronal loss is associated with impaired TH axonal transport, altered striatal GABAergic interneuron TH expression, and compensatory neuronal plasticity. This is an emerging model-derived mechanism, not yet established as a universal human disease feature.

GABAergic neuron CL:0000617

axonal transport GO:0098930 ↓ DECREASED regulation of neuronal synaptic plasticity GO:0048168 ↕ DYSREGULATED

striatum UBERON:0002435

Downstream

Dopamine-Responsive Motor Circuit Dysfunction

Show evidence (1 reference)

PMID:41872043 SUPPORT Model Organism

"No changes were observed in Th-mRNA expression, and the decreased level of TH in the concrete brain areas in Th-ki mice appears to be due to defective TH protein axonal transport."

The model directly supports defective axonal delivery of TH protein.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Digestive 2

Constipation FREQUENT HP:0002019

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002019 | Constipation | Frequent (79-30%) |"

Orphanet lists constipation as frequent.

Feeding Difficulties FREQUENT HP:0011968

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0011968 | Feeding difficulties | Frequent (79-30%) |"

Orphanet lists feeding difficulties as frequent.

Eye 1

Ptosis FREQUENT HP:0000508

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0000508 | Ptosis | Frequent (79-30%) |"

Orphanet lists ptosis as frequent.

Head and Neck 1

Excessive Salivation FREQUENT HP:0003781

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0003781 | Excessive salivation | Frequent (79-30%) |"

Orphanet lists excessive salivation as frequent.

Limbs 2

Pes Cavus FREQUENT HP:0001761

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001761 | Pes cavus | Frequent (79-30%) |"

Orphanet lists pes cavus as frequent.

Talipes Equinovarus FREQUENT HP:0001762

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001762 | Talipes equinovarus | Frequent (79-30%) |"

Orphanet lists talipes equinovarus as frequent.

Musculoskeletal 2

Hypotonia FREQUENT HP:0001252

Show evidence (2 references)

ORPHA:101150 SUPPORT Other

"| HP:0001252 | Hypotonia | Frequent (79-30%) |"

Orphanet lists hypotonia as frequent.

PMID:20301610 SUPPORT Other

"Affected infants demonstrate truncal hypotonia and parkinsonian symptoms and signs (hypokinesia, rigidity of extremities, and/or tremor)."

GeneReviews directly supports hypotonia in the infantile TH deficiency spectrum.

Rigidity FREQUENT HP:0002063

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002063 | Rigidity | Frequent (79-30%) |"

Orphanet lists rigidity as frequent.

Nervous System 10

Irritability FREQUENT HP:0000737

Show evidence (2 references)

ORPHA:101150 SUPPORT Other

"| HP:0000737 | Irritability | Frequent (79-30%) |"

Orphanet lists irritability as frequent.

PMID:20301610 SUPPORT Other

GeneReviews supports irritability in severe TH deficiency.

Delayed Speech and Language Development FREQUENT HP:0000750

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0000750 | Delayed speech and language development | Frequent (79-30%) |"

Orphanet lists delayed speech and language development as frequent.

Ataxia FREQUENT HP:0001251

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001251 | Ataxia | Frequent (79-30%) |"

Orphanet lists ataxia as frequent.

Lethargy FREQUENT HP:0001254

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001254 | Lethargy | Frequent (79-30%) |"

Orphanet lists lethargy as frequent.

Mild Intellectual Disability OCCASIONAL HP:0001256

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001256 | Intellectual disability, mild | Occasional (29-5%) |"

Orphanet lists mild intellectual disability as occasional.

Motor Delay FREQUENT HP:0001270

Show evidence (2 references)

ORPHA:101150 SUPPORT Other

"| HP:0001270 | Motor delay | Frequent (79-30%) |"

Orphanet lists motor delay as frequent.

PMID:20301610 SUPPORT Other

"In contrast to TH-deficient DRD, motor milestones are overtly delayed in this severe form."

GeneReviews supports motor delay in severe TH deficiency.

Parkinsonism FREQUENT HP:0001300

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001300 | Parkinsonism | Frequent (79-30%) |"

Orphanet lists parkinsonism as frequent.

Myoclonus FREQUENT HP:0001336

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001336 | Myoclonus | Frequent (79-30%) |"

Orphanet lists myoclonus as frequent.

Gait Ataxia FREQUENT HP:0002066

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002066 | Gait ataxia | Frequent (79-30%) |"

Orphanet lists gait ataxia as frequent.

Bradykinesia FREQUENT HP:0002067

Show evidence (2 references)

ORPHA:101150 SUPPORT Other

"| HP:0002067 | Bradykinesia | Frequent (79-30%) |"

Orphanet lists bradykinesia as frequent.

PMID:30383639 SUPPORT Human Clinical

"RATIONALE: Autosomal-recessive dopa-responsive dystonia (DRD) is a rare clinical disorder presenting as bradykinesia, dystonia, tremor and even severe encephalopathy, and caused by tyrosine hydroxylase deficiency (THD)."

Case-report abstract supports bradykinesia in AR DRD.

Constitutional 1

Night Sweats FREQUENT HP:0030166

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0030166 | Night sweats | Frequent (79-30%) |"

Orphanet lists night sweats as frequent.

Other 13

Axial Hypotonia FREQUENT HP:0008936

Show evidence (2 references)

PMID:20301610 SUPPORT Other

"Affected infants demonstrate truncal hypotonia and parkinsonian symptoms and signs (hypokinesia, rigidity of extremities, and/or tremor)."

GeneReviews directly supports axial/truncal hypotonia.

PMID:36101825 SUPPORT Human Clinical

"After viral infections or vaccination, she developed lethargy, worsened tremor, language, and motor regression including severe axial hypotonia, recuperating over several weeks of intensive rehabilitation but with residual tremor and mild lower limb spasticity."

A human case documents severe axial hypotonia during decompensation.

Brisk Reflexes FREQUENT HP:0001348

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0001348 | Brisk reflexes | Frequent (79-30%) |"

Orphanet lists brisk reflexes as frequent.

Extrapyramidal Motor Dysfunction FREQUENT Abnormality of extrapyramidal motor function HP:0002071

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002071 | Abnormality of extrapyramidal motor function | Frequent (79-30%) |"

Orphanet lists abnormal extrapyramidal motor function as frequent.

Postural Tremor FREQUENT HP:0002174

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002174 | Postural tremor | Frequent (79-30%) |"

Orphanet lists postural tremor as frequent.

Hypokinesia FREQUENT HP:0002375

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002375 | Hypokinesia | Frequent (79-30%) |"

Orphanet lists hypokinesia as frequent.

Lower Limb Hyperreflexia FREQUENT HP:0002395

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%) |"

Orphanet lists lower limb hyperreflexia as frequent.

Progressive Encephalopathy VERY_RARE HP:0002448

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0002448 | Progressive encephalopathy | Very rare (<4-1%) |"

Orphanet lists progressive encephalopathy as very rare.

Limb Dystonia FREQUENT HP:0002451

Show evidence (2 references)

ORPHA:101150 SUPPORT Other

"| HP:0002451 | Limb dystonia | Frequent (79-30%) |"

Orphanet lists limb dystonia as frequent.

PMID:20301610 SUPPORT Other

GeneReviews supports lower-limb dystonia as a typical initial symptom.

Babinski Sign FREQUENT HP:0003487

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0003487 | Babinski sign | Frequent (79-30%) |"

Orphanet lists Babinski sign as frequent.

Decreased CSF Homovanillic Acid FREQUENT Decreased CSF homovanillic acid concentration HP:0003785

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent (79-30%) |"

Orphanet lists decreased CSF homovanillic acid concentration as frequent.

Focal Dystonia FREQUENT HP:0004373

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0004373 | Focal dystonia | Frequent (79-30%) |"

Orphanet lists focal dystonia as frequent.

Generalized Dystonia OCCASIONAL HP:0007325

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0007325 | Generalized dystonia | Occasional (29-5%) |"

Orphanet lists generalized dystonia as occasional.

Oculogyric Crisis FREQUENT HP:0010553

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| HP:0010553 | Oculogyric crisis | Frequent (79-30%) |"

Orphanet lists oculogyric crisis as frequent.

🧬

Genetic Associations

TH biallelic pathogenic variants (Causative biallelic loss-of-function pathogenic variants)

Gene: TH hgnc:11782 relationship_type: CAUSATIVE variant_origin: GERMLINE

Autosomal recessive inheritance

Show evidence (3 references)

PMID:20301610 SUPPORT Other

"The diagnosis of TH deficiency is established in a proband by identification of biallelic pathogenic variants in TH by molecular genetic testing."

Supports biallelic TH pathogenic variants as diagnostic.

ORPHA:101150 SUPPORT Other

"| TH | tyrosine hydroxylase | hgnc:11782 | Disease-causing germline mutation(s) in |"

Orphanet lists TH as a disease-causing gene.

PMID:41121981 SUPPORT Human Clinical

"Among the 36 identified variants, the predominant were p.R233H (37.3%), p.R153X (10.8%), and p.Q232X (6.9%)."

The large pediatric cohort documents recurrent missense and nonsense alleles.

🗃️

External Assertions

iNTD longitudinal patient registry

International Working Group on Neurotransmitter related Disorders patient registry iNTD

International longitudinal registry for primary and secondary neurotransmitter disorders, including TH deficiency, with annual clinical follow-up.

Show evidence (1 reference)

PMID:27830117 SUPPORT Human Clinical

"The newly established iNTD patient registry for neurotransmitter related diseases collects longitudinal data on the natural disease course, approach to diagnosis, therapeutic strategies, and quality of life of affected patients."

This publication defines the registry and its longitudinal disease, diagnostic, treatment, and quality-of-life scope.

💊

Medical Actions

Severity-adapted levodopa with a decarboxylase inhibitor

Action: Pharmacotherapy NCIT:C15986

Agent: levodopa CHEBI:15765 carbidopa CHEBI:3395

Levodopa plus carbidopa or another peripheral decarboxylase inhibitor bypasses the TH block and is first-line therapy. Start low and titrate dynamically: mild DRD usually responds completely, infantile parkinsonism often improves incompletely and slowly, and severe encephalopathy may be extremely sensitive with dose-limiting dyskinesia.

Mechanism Target:

BYPASSES Biallelic TH Loss of Function

Show evidence (1 reference)

PMID:41215497 SUPPORT Other

"L-dopa/decarboxylase inhibitor (DCI) supplementation is often the first-line treatment, and most patients have a good therapeutic response."

Levodopa supplies the product downstream of the impaired TH step.

RESTORES Cerebral Catecholamine Deficiency

Show evidence (1 reference)

PMID:20301610 SUPPORT Other

"All individuals with TH-deficient DRD demonstrate complete responsiveness of symptoms to levodopa (with a decarboxylase inhibitor)."

Clinical response supports functional restoration of dopamine supply.

Target Phenotypes: Limb dystonia HP:0002451 Parkinsonism HP:0001300 Rigidity HP:0002063

Show evidence (4 references)

PMID:41215497 SUPPORT Other

"L-dopa/decarboxylase inhibitor (DCI) supplementation is often the first-line treatment, and most patients have a good therapeutic response."

The current consensus identifies levodopa/DCI as first-line therapy.

PMID:20301610 SUPPORT Other

"All individuals with TH-deficient DRD demonstrate complete responsiveness of symptoms to levodopa (with a decarboxylase inhibitor)."

GeneReviews supports levodopa with a decarboxylase inhibitor for TH-deficient DRD.

PMID:20301610 SUPPORT Other

"Individuals with TH-deficient infantile parkinsonism with motor delay demonstrate a marked response to levodopa."

GeneReviews supports marked levodopa response in the severe motor-delay subtype.

+ 1 more reference

Monoamine oxidase inhibitor adjunct

Action: Pharmacotherapy NCIT:C15986

Agent: selegiline CHEBI:50217

Selegiline or another monoamine oxidase inhibitor may be considered by a specialist when levodopa alone gives inadequate control or severe disease limits titration. Evidence is limited to small observational experience; the consensus explicitly calls for further evaluation.

Mechanism Target:

MODULATES Cerebral Catecholamine Deficiency

Show evidence (1 reference)

PMID:20823027 SUPPORT Human Clinical

"Levodopa was the mainstay of treatment, and early addition of selegiline resulted in a remarkable response in some patients."

Selegiline can augment catecholaminergic treatment in selected patients.

Target Phenotypes: Limb dystonia HP:0002451 Parkinsonism HP:0001300

Show evidence (2 references)

PMID:20823027 SUPPORT Human Clinical

"Levodopa was the mainstay of treatment, and early addition of selegiline resulted in a remarkable response in some patients."

A small human series reports adjunctive benefit in some patients.

PMID:41215497 SUPPORT Other

"Therefore, alternative treatment options, such as monoamine oxidase (MAO) inhibitors, must be evaluated to optimize motor symptom control."

The consensus identifies MAO inhibitors as an option requiring further evaluation.

Multidisciplinary developmental and supportive care

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Movement-disorder follow-up, neurodevelopmental surveillance, physical and occupational therapy, speech/feeding support, nutrition, and management of comorbidities complement pharmacotherapy, especially when severe deficits persist.

Target Phenotypes: Motor delay HP:0001270 Feeding difficulties HP:0011968

Show evidence (1 reference)

PMID:41215497 SUPPORT Other

"Additionally, a multidisciplinary treatment approach should be utilized to monitor neurocognitive development and other comorbidities that may occur in THD."

The consensus recommends multidisciplinary monitoring and care.

Avoid antidopaminergic agents

Action: supportive care Ontology label: Supportive Care NCIT:C15747

The prokinetic agent metoclopramide (Reglan) and other related antidopaminergic agents should be avoided because they can acutely worsen the dopamine deficiency that underlies TH-deficient dopa-responsive dystonia.

Show evidence (1 reference)

PMID:20301610 SUPPORT Other

"Agents/circumstances to avoid: The prokinetic agent Reglan® and other related antidopaminergic agents."

GeneReviews explicitly lists the prokinetic agent metoclopramide (Reglan) and other related antidopaminergic agents as agents to avoid in tyrosine hydroxylase deficiency, since they can exacerbate the underlying dopamine deficit.

🔬

Biochemical Markers

Low CSF homovanillic acid (DECREASED)

Pathograph Readouts

Readout Of Cerebral Catecholamine Deficiency Negative Diagnostic

Reduced CSF HVA reports reduced central dopamine turnover.

Show evidence (1 reference)

PMID:20430833 SUPPORT Human Clinical

"Decreased cerebrospinal fluid concentrations of homovanillic acid and 3-methoxy-4-hydroxyphenylethylene glycol, with normal 5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the biochemical hallmark of tyrosine hydroxylase deficiency."

The clinical study establishes low HVA as a disease readout.

Show evidence (2 references)

PMID:41215497 SUPPORT Other

"The diagnosis is suggested by the detection of low CSF homovanillic acid (HVA) and confirmed by identifying biallelic pathogenic variants in the TH gene."

The consensus identifies low CSF HVA as the key biochemical clue.

PMID:20430833 SUPPORT Human Clinical

The 36-patient study establishes the characteristic CSF pattern.

Low CSF 3-methoxy-4-hydroxyphenylethylene glycol (DECREASED)

Pathograph Readouts

Readout Of Cerebral Catecholamine Deficiency Negative Diagnostic

Reduced CSF MHPG reports reduced central norepinephrine turnover.

Show evidence (1 reference)

PMID:20430833 SUPPORT Human Clinical

The clinical study establishes low MHPG as a disease readout.

Show evidence (1 reference)

PMID:20430833 SUPPORT Human Clinical

The clinical study establishes decreased CSF MHPG.

Normal CSF 5-hydroxyindoleacetic acid (NORMAL)

Show evidence (1 reference)

PMID:20430833 SUPPORT Human Clinical

The clinical study establishes normal CSF 5-HIAA as part of the signature.

🔬

Diagnosis

Molecular genetic testing (Positive)

Confirm TH deficiency by identifying pathogenic or likely pathogenic variants on both TH alleles. Molecular confirmation is essential because the phenotype overlaps several dopamine and BH4 pathway disorders.

Show evidence (2 references)

PMID:41215497 SUPPORT Other

"The diagnosis is suggested by the detection of low CSF homovanillic acid (HVA) and confirmed by identifying biallelic pathogenic variants in the TH gene."

The current consensus requires biallelic TH confirmation.

PMID:20301610 SUPPORT Other

"The diagnosis of TH deficiency is established in a proband by identification of biallelic pathogenic variants in TH by molecular genetic testing."

GeneReviews supports molecular genetic testing for TH deficiency.

CSF neurotransmitter metabolite testing (Positive)

The characteristic pretreatment pattern is low HVA and MHPG with normal 5-HIAA. HVA and the HVA/5-HIAA ratio can correlate with severity, but age-adjusted sampling and molecular confirmation are required.

Show evidence (2 references)

PMID:20430833 SUPPORT Human Clinical

The clinical cohort defines the distinguishing CSF pattern.

PMID:33996491 SUPPORT Human Clinical

"This study confirms that cerebrospinal fluid is the most informative body fluid to measure monoamine neurotransmitter metabolites when AADC or TH deficiency is suspected, and that routine follow-up of cerebrospinal fluid measurements to estimate treatment response is not needed."

This study supports CSF for diagnosis but not routine response monitoring.

Levodopa responsiveness (Supportive but not required)

A marked, sustained response strongly supports a dopamine-synthesis disorder, especially in mild TH-deficient DRD. Incomplete response or dose-limiting dyskinesia in severe disease does not exclude TH deficiency.

Show evidence (2 references)

PMID:20301610 SUPPORT Other

"All individuals with TH-deficient DRD demonstrate complete responsiveness of symptoms to levodopa (with a decarboxylase inhibitor)."

GeneReviews supports levodopa responsiveness in the mild subtype.

PMID:41215497 SUPPORT Other

"However, initiation of therapy can be challenging in patients with severe disease forms who develop L-dopa/DCI-induced dyskinesia."

The consensus cautions that severe disease may have treatment-limiting dyskinesia.

Peripheral monoamine metabolite testing (Not exclusionary)

Normal urine or blood catecholamine metabolites do not rule out TH deficiency. Peripheral measurements are less informative than CSF, and urinary dopamine is often normal despite the central metabolic block.

Show evidence (1 reference)

PMID:33996491 SUPPORT Human Clinical

"However, in many patients with TH or AADC deficiency dopamine in urine is normal or increased thereby not reflecting the metabolic block."

Normal or increased urinary dopamine cannot exclude TH deficiency.

📊

Prevalence

Europe

Point Prevalence 0.1–0.9 per 100,000 1–9 per 1,000,000

Orphanet records European point prevalence in the one-to-nine per million range.

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"| 1-9 / 1 000 000 | Europe | Point prevalence | ORPHANET |"

Orphanet lists European point prevalence.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Autosomal Recessive Dopa-Responsive Dystonia:

GTP cyclohydrolase 1-deficient dopa-responsive dystonia MONDO:0971063

Overlapping Features GCH1-deficient DRD shares childhood dystonia, diurnal fluctuation, and a dramatic levodopa response with mild TH deficiency.

Distinguishing Features

Usually a heterozygous GCH1 disorder with autosomal dominant inheritance and reduced penetrance
Intellectual, cerebellar, and autonomic manifestations generally do not occur in classic GCH1-deficient DRD
Molecular testing identifies GCH1 rather than biallelic TH variants

Show evidence (2 references)

PMID:20301681 SUPPORT Other

"The diagnosis of GTPCH1-deficient DRD is established in a proband by identification of a heterozygous pathogenic variant in GCH1 by molecular genetic testing."

GeneReviews provides the decisive molecular distinction.

PMID:20301681 SUPPORT Other

"Intellectual, cerebellar, sensory, and autonomic disturbances generally do not occur."

This contrasts classic GCH1 disease with severe TH-deficiency manifestations.

Sepiapterin reductase deficiency

Overlapping Features Biallelic SPR disease is another recessive, levodopa-responsive neurotransmitter disorder and can present with dystonia, developmental impairment, oculogyric crises, and diurnal fluctuation.

Distinguishing Features

Biallelic SPR rather than TH variants
BH4-pathway dysfunction can reduce serotonin as well as catecholamine synthesis
The TH-deficiency hallmark retains normal CSF 5-HIAA

Show evidence (2 references)

PMID:34834538 SUPPORT Other

"This impairment may be due to the fact of a deficiency in GTP cyclohydrolase I (GTPCHI, GCH1 gene), sepiapterin reductase (SR), tyrosine hydroxylase (TH), or 6-pyruvoyl tetrahydrobiopterin synthase (PTPS) enzyme functions."

The review places SPR and TH defects within the DRD differential.

PMID:20430833 SUPPORT Human Clinical

Normal CSF 5-HIAA supports TH rather than a combined monoamine defect.

Aromatic L-amino acid decarboxylase deficiency MONDO:0012084

Overlapping Features AADC deficiency overlaps with severe TH deficiency through early hypotonia, developmental delay, dystonia, oculogyric crises, and autonomic dysfunction.

Distinguishing Features

Biallelic DDC rather than TH variants
Low CSF HVA and 5-HIAA with elevated 3-O-methyldopa, rather than normal 5-HIAA
Peripheral 3-O-methyldopa is a promising AADC marker but not a TH-deficiency marker

Show evidence (2 references)

PMID:19172410 SUPPORT Human Clinical

"In CSF all patients revealed the pattern typical of AADC with decreased concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated concentration of 3-ortho-methyldopa."

The AADC CSF profile differs from the normal 5-HIAA of TH deficiency.

PMID:33996491 SUPPORT Human Clinical

"3-O-methyldopa in dried blood spots and vanillactic acid in urine are promising peripheral biomarkers for diagnosis of AADC deficiency."

The peripheral markers help distinguish AADC from TH deficiency.

Cerebral palsy and static motor disorders

Overlapping Features Infantile hypotonia, spasticity, dystonia, motor delay, and normal or nonspecific imaging can lead to a cerebral-palsy label. Diurnal fluctuation, episodic regression, CSF neurotransmitter abnormalities, and biallelic TH variants establish a treatable metabolic disorder instead.

Distinguishing Features

Diurnal fluctuation or episodic decompensation
Low CSF HVA and MHPG with normal 5-HIAA
Biallelic pathogenic TH variants and a levodopa response

Show evidence (1 reference)

PMID:27830117 SUPPORT Human Clinical

"As a consequence, patients and their parents often traverse a stressful odyssey from doctor to doctor with frequent misdiagnoses, such as cerebral palsy, myasthenia gravis or seizure disorders"

The registry-network report identifies cerebral palsy as a frequent misdiagnosis.

🔬

Clinical Trials

NCT03655223 NOT_APPLICABLE ACTIVE_NOT_RECRUITING

Early Check is a broad voluntary newborn-screening implementation study in North and South Carolina. Its current condition panel includes autosomal recessive Segawa syndrome; it is not a TH-deficiency treatment trial.

Show evidence (1 reference)

clinicaltrials:NCT03655223 SUPPORT Human Clinical

"Early Check provides voluntary screening of newborns for a selected panel of conditions."

The registry record defines the newborn-screening design.

NCT05687474 NOT_APPLICABLE COMPLETED

Baby Detect evaluated targeted genomic newborn screening in Wallonia-Brussels for 126 treatable severe early-onset genetic diseases, including autosomal recessive Segawa syndrome. It was a screening program, not a therapeutic trial.

Show evidence (1 reference)

clinicaltrials:NCT05687474 SUPPORT Human Clinical

"Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes."

The registry record defines the completed targeted genomic screening program.

🧫

Experimental Models

Patient-derived THD iPSC dopaminergic neurons IPSC_DERIVED_MODEL

Patient-derived neurons reproduce reduced TH and dopamine metabolites, shortened neurites, and reduced arborization. Levodopa rescued mature THD-A neurons, while precursor-stage treatment prevented defects in THD-B, suggesting phenotype-specific response and a possible developmental window.

Organism

human NCBITaxon:9606

Cell source

Patient-derived induced pluripotent stem cells differentiated into dopaminergic neurons, with healthy and gene-corrected isogenic controls

Publication

PMID:36740977

Pathograph links

Biallelic TH Loss of Function Patient neurons model reduced TH abundance caused by biallelic disease alleles.

Show evidence (1 reference)

PMID:36740977 SUPPORT In Vitro

"Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls."

The patient-derived model recapitulates reduced TH expression.

Cerebral Catecholamine Deficiency Reduced dopamine metabolites model the central biochemical defect.

Show evidence (1 reference)

PMID:36740977 SUPPORT In Vitro

"Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls."

The model reproduces dopamine-metabolite depletion.

Findings

THD neurons have reduced neurite length and arborization.

"THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects."

Show evidence (1 reference)

PMID:36740977 SUPPORT In Vitro

"Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC."

Patient-derived neurons reveal a cellular neurodevelopmental phenotype.

Levodopa response depends on phenotype and treatment timing in this model.

"L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn."

Show evidence (1 reference)

PMID:36740977 SUPPORT In Vitro

"Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD."

The experiment supports a model-specific developmental treatment window.

Show evidence (1 reference)

PMID:36740977 SUPPORT In Vitro

"Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management."

The study validates the model for mechanistic and treatment research.

BH4 stabilization assay in THD patient-derived neurons IPSC_DERIVED_MODEL

Variant-stratified patient neurons were used to test whether the natural TH cofactor BH4 can act as a pharmacologic stabilizer and restore TH abundance and dopamine.

Organism

human NCBITaxon:9606

Cell source

Dopaminergic neurons differentiated from iPSCs carrying homozygous R233H (THD-A) or compound R328W/T399M (THD-B) TH variants

Publication

PMID:38196161

Pathograph links

Biallelic TH Loss of Function BH4 tests rescue of variant-associated TH instability.

Show evidence (1 reference)

PMID:38196161 SUPPORT In Vitro

"We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells."

BH4 increases TH and dopamine in the responsive cellular genotype.

Findings

BH4 increased TH, dopamine, and TH-positive cells in control and THD-A neurons.

"We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells."

Show evidence (1 reference)

PMID:38196161 SUPPORT In Vitro

"We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells."

The patient-neuron experiment shows variant-dependent biochemical rescue.

Show evidence (1 reference)

PMID:38196161 SUPPORT In Vitro

"In conclusion, our study demonstrates the stabilizing effects of BH4 on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes."

The study supports BH4 as a preclinical TH-stabilization strategy.

🐁

Animal Models

Th-p.R203H knock-in mouse corresponding to human TH p.R202H/p.R233H disease nomenclature Mus musculus

This knock-in model has reduced TH and dopamine across several brain regions, motor impairment, defective TH protein axonal transport, altered striatal interneuron markers, and compensatory plasticity without dopaminergic neuronal degeneration. BH4 improved motor outcomes in preclinical treatment experiments.

Species

Mus musculus

Genotype

Th-p.R203H knock-in mouse corresponding to human TH p.R202H/p.R233H disease nomenclature

Genes

Th MGI:98735

Show evidence (2 references)

PMID:41872043 SUPPORT Model Organism

"Th-ki mice displayed significantly reduced TH, especially in the striatum, but also in the cortex, olfactory bulb, cerebellum, substantia nigra, globus pallidus, and spinal cord, a decrease that is not associated with dopaminergic neuronal degeneration."

The knock-in mouse recapitulates regional TH deficiency without neuron loss.

PMID:38196161 SUPPORT Model Organism

"Importantly, treatment with BH4 significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy)."

BH4 produces preclinical motor rescue in the knock-in model.

{ }

Source YAML

click to show

name: Autosomal Recessive Dopa-Responsive Dystonia
creation_date: "2026-05-06T07:55:00Z"
category: Genetic
parents:
- Dopa-responsive dystonia
- Inborn Error of Metabolism
- Movement Disorder
disease_term:
  preferred_term: TH-deficient dopa-responsive dystonia
  term:
    id: MONDO:0011551
    label: TH-deficient dopa-responsive dystonia
synonyms:
- Autosomal recessive Segawa syndrome
- DYT5b
- Tyrosine hydroxylase deficiency
- Tyrosine hydroxylase-deficient dopa-responsive dystonia
description: >-
  TH-deficient dopa-responsive dystonia is a very rare autosomal recessive
  neurometabolic disorder caused by biallelic pathogenic variants in TH.
  Reduced tyrosine hydroxylase activity limits the rate-limiting conversion of
  tyrosine to L-dopa and depletes dopamine and other catecholamines in the
  central nervous system. Clinical expression is continuous, ranging from
  childhood-onset, levodopa-responsive dystonia to infantile parkinsonism with
  motor delay and severe early encephalopathy with variable levodopa response.
notes: >-
  MONDO:0011551, ORPHA:101150, and OMIM:605407 map this entity to TH
  deficiency. The 2025-12-09 Orphadata snapshot also attaches TSPOAP1 to
  ORPHA:101150, but the cited TSPOAP1 primary study concerns a distinct
  presynaptic autosomal recessive dystonia rather than TH-deficient,
  dopa-responsive disease. TSPOAP1 is therefore excluded from this
  MONDO-anchored entry.
external_assertions:
- name: Gene2Phenotype TH-related DOPA-responsive dystonia assertion
  source: Gene2Phenotype
  assertion_type: gene_disease_validity
  external_id: G2P01562
  url: https://www.ebi.ac.uk/gene2phenotype/
  description: >-
    The 2026-06-28 Gene2Phenotype DD release classifies the biallelic,
    loss-of-function TH relationship as definitive and cites nine reviewed
    publications.
  evidence:
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Autosomal recessive tyrosine hydroxylase deficiency (THD) leads to
      clinical phenotypes reflecting the deficiency of dopamine, norepinephrine,
      or epinephrine in the central nervous system (CNS), presenting along a
      continuous spectrum from mild to severe forms of the disease.
    explanation: >-
      The current consensus guideline independently supports the curated
      biallelic TH gene-disease relationship and phenotypic spectrum.
- name: iNTD longitudinal patient registry
  source: International Working Group on Neurotransmitter related Disorders
  assertion_type: patient_registry
  external_id: iNTD
  url: https://intd-registry.org/
  description: >-
    International longitudinal registry for primary and secondary
    neurotransmitter disorders, including TH deficiency, with annual clinical
    follow-up.
  evidence:
  - reference: PMID:27830117
    reference_title: "The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The newly established iNTD patient registry for neurotransmitter related
      diseases collects longitudinal data on the natural disease course,
      approach to diagnosis, therapeutic strategies, and quality of life of
      affected patients.
    explanation: >-
      This publication defines the registry and its longitudinal disease,
      diagnostic, treatment, and quality-of-life scope.
has_subtypes:
- name: TH-deficient DRD
  display_name: TH-deficient dopa-responsive dystonia
  description: >-
    Mild TH deficiency with childhood lower-limb dystonia, gait disturbance,
    possible diurnal fluctuation, and complete levodopa responsiveness.
  review_notes: >-
    A clinical phenotype on a continuous severity spectrum rather than a
    genetically distinct subtype.
  evidence:
  - reference: PMID:20301610
    reference_title: Tyrosine Hydroxylase Deficiency.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In individuals with TH-deficient dopa-responsive dystonia (DYT5b, DYT-TH),
      onset is between age 12 months and 12 years; initial symptoms are typically
      lower-limb dystonia and/or difficulty in walking.
    explanation: GeneReviews defines the mild TH-deficient DRD phenotype.
- name: Infantile parkinsonism
  display_name: TH-deficient infantile parkinsonism with motor delay
  description: >-
    Severe TH deficiency presenting in infancy with motor delay, hypotonia, and
    parkinsonian signs including hypokinesia, rigidity, and tremor.
  review_notes: >-
    A clinical phenotype on a continuous severity spectrum rather than a
    genetically distinct subtype.
  evidence:
  - reference: PMID:20301610
    reference_title: Tyrosine Hydroxylase Deficiency.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In most individuals with TH-deficient infantile parkinsonism with motor
      delay, onset is between age three and 12 months.
    explanation: GeneReviews defines the infantile parkinsonism phenotype.
- name: Progressive infantile encephalopathy
  display_name: TH-deficient progressive infantile encephalopathy
  description: >-
    Very severe early-onset TH deficiency with marked motor delay, hypotonia,
    hyperreflexia, oculogyric crises, ptosis, intellectual disability, lethargy,
    irritability, sweating, and drooling.
  review_notes: >-
    A clinical phenotype on a continuous severity spectrum rather than a
    genetically distinct subtype.
  evidence:
  - reference: PMID:20301610
    reference_title: Tyrosine Hydroxylase Deficiency.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In individuals with TH-deficient progressive infantile encephalopathy,
      onset is before age three to six months.
    explanation: GeneReviews defines the very severe early-onset phenotype.
references:
- reference: ORPHA:101150
  title: Autosomal recessive dopa-responsive dystonia
  found_in:
  - Autosomal_Recessive_Dopa_Responsive_Dystonia-deep-research-fallback.md
  findings:
  - statement: >-
      Orphanet defines autosomal recessive dopa-responsive dystonia as a very
      rare neurometabolic disorder spanning DRD to progressive infantile
      encephalopathy.
    supporting_text: >-
      A very rare neurometabolic disorder characterized by a spectrum of
      symptoms ranging from those seen in dopa-responsive dystonia (DRD) to
      progressive infantile encephalopathy.
    evidence:
    - reference: ORPHA:101150
      reference_title: "Autosomal recessive dopa-responsive dystonia"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        A very rare neurometabolic disorder characterized by a spectrum of
        symptoms ranging from those seen in dopa-responsive dystonia (DRD) to
        progressive infantile encephalopathy.
      explanation: >-
        Orphanet definition supports the disease scope and severity spectrum.
- reference: PMID:20301610
  title: Tyrosine Hydroxylase Deficiency.
  tags:
  - GeneReviews
  found_in:
  - Autosomal_Recessive_Dopa_Responsive_Dystonia-deep-research-fallback.md
  findings:
  - statement: >-
      GeneReviews supports TH deficiency subtypes, biallelic molecular
      diagnosis, autosomal recessive inheritance, and levodopa management.
    supporting_text: >-
      GeneReviews describes TH-deficient DRD, infantile parkinsonism with motor
      delay, and progressive infantile encephalopathy, and states that diagnosis
      is established by biallelic TH pathogenic variants.
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The diagnosis of TH deficiency is established in a proband by
        identification of biallelic pathogenic variants in TH by molecular
        genetic testing.
      explanation: GeneReviews states the molecular diagnostic criterion.
- reference: PMID:41215497
  title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
  findings:
  - statement: >-
      The 2025 iNTD consensus supports low CSF HVA followed by biallelic TH
      confirmation, levodopa/decarboxylase inhibitor as first-line treatment,
      careful management of severe-form dyskinesia, and multidisciplinary care.
    supporting_text: >-
      The diagnosis is suggested by the detection of low CSF homovanillic acid
      (HVA) and confirmed by identifying biallelic pathogenic variants in the TH
      gene.
    evidence:
    - reference: PMID:41215497
      reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The diagnosis is suggested by the detection of low CSF homovanillic
        acid (HVA) and confirmed by identifying biallelic pathogenic variants
        in the TH gene.
      explanation: The current consensus states the diagnostic sequence.
- reference: PMID:20430833
  title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
  findings:
  - statement: >-
      A 36-patient study established the type A/type B clinical spectrum, the
      characteristic CSF metabolite pattern, and broad levodopa treatability.
    supporting_text: >-
      Decreased cerebrospinal fluid concentrations of homovanillic acid and
      3-methoxy-4-hydroxyphenylethylene glycol, with normal
      5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
      biochemical hallmark of tyrosine hydroxylase deficiency.
    evidence:
    - reference: PMID:20430833
      reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Decreased cerebrospinal fluid concentrations of homovanillic acid and
        3-methoxy-4-hydroxyphenylethylene glycol, with normal
        5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
        biochemical hallmark of tyrosine hydroxylase deficiency.
      explanation: The cohort defines the characteristic CSF signature.
- reference: PMID:41121981
  title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
  findings:
  - statement: >-
      The largest single-center pediatric cohort found movement disorders in
      96.1%, developmental delay in 88.2%, autonomic symptoms in 51.0%, and
      genotype-associated levodopa dose differences.
    supporting_text: >-
      Movement disorders were present in 96.1% of cases, with developmental
      delay observed in 88.2%, and autonomic symptoms in 51.0%.
    evidence:
    - reference: PMID:41121981
      reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Movement disorders were present in 96.1% of cases, with developmental
        delay observed in 88.2%, and autonomic symptoms in 51.0%.
      explanation: The pediatric cohort quantifies major clinical domains.
- reference: PMID:36740977
  title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
  findings:
  - statement: >-
      Patient-derived dopaminergic neurons show dopamine-metabolite depletion,
      reduced TH, neurite defects, phenotype-dependent levodopa rescue, and a
      possible developmental treatment window.
    supporting_text: >-
      THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH
      expression, when compared to controls.
    evidence:
    - reference: PMID:36740977
      reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH
        expression, when compared to controls.
      explanation: Patient-derived neurons reproduce the core biochemical defect.
- reference: PMID:38196161
  title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
  findings:
  - statement: >-
      BH4 increased TH and dopamine in patient-derived neurons and improved
      motor outcomes in a knock-in mouse, supporting a variant-dependent
      preclinical proteostasis strategy.
    supporting_text: >-
      Treatment with BH4 significantly improved motor function in these mice,
      as demonstrated by increased latency on the rotarod test and improved
      horizontal activity (catalepsy).
    evidence:
    - reference: PMID:38196161
      reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Importantly, treatment with BH4 significantly improved motor function
        in these mice, as demonstrated by increased latency on the rotarod test
        and improved horizontal activity (catalepsy).
      explanation: The knock-in mouse provides preclinical motor-rescue evidence.
- reference: PMID:41872043
  title: "Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity."
  findings:
  - statement: >-
      A Th-p.R203H knock-in model supports defective TH axonal transport,
      altered striatal inhibitory circuitry, and compensatory plasticity
      without dopaminergic neuron degeneration.
    supporting_text: >-
      TH deficiency disrupts striatal inhibitory circuitry and triggers
      compensatory neuronal plasticity, without causing neuronal degeneration.
    evidence:
    - reference: PMID:41872043
      reference_title: "Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Overall, our findings demonstrate that TH deficiency disrupts striatal
        inhibitory circuitry and triggers compensatory neuronal plasticity,
        without causing neuronal degeneration.
      explanation: The model identifies a circuit-level consequence beyond transmitter depletion.
- reference: PMID:33996491
  title: Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment.
  findings:
  - statement: >-
      CSF remains the most informative compartment for monoamine-metabolite
      diagnosis; urinary dopamine can be normal and routine CSF monitoring does
      not reliably measure clinical treatment response.
    supporting_text: >-
      This study confirms that cerebrospinal fluid is the most informative body
      fluid to measure monoamine neurotransmitter metabolites when AADC or TH
      deficiency is suspected.
    evidence:
    - reference: PMID:33996491
      reference_title: Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This study confirms that cerebrospinal fluid is the most informative
        body fluid to measure monoamine neurotransmitter metabolites when AADC
        or TH deficiency is suspected, and that routine follow-up of
        cerebrospinal fluid measurements to estimate treatment response is not
        needed.
      explanation: The body-fluid study defines the diagnostic and monitoring roles of CSF.
- reference: PMID:36101825
  title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
  findings:
  - statement: >-
      Infection- or vaccination-associated episodic regression and hypotonia
      can occur in mild TH deficiency and may respond rapidly to
      levodopa/carbidopa.
    supporting_text: >-
      After viral infections or vaccination, she developed lethargy, worsened
      tremor, language, and motor regression including severe axial hypotonia.
    evidence:
    - reference: PMID:36101825
      reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        After viral infections or vaccination, she developed lethargy,
        worsened tremor, language, and motor regression including severe axial
        hypotonia, recuperating over several weeks of intensive rehabilitation
        but with residual tremor and mild lower limb spasticity.
      explanation: The case and literature review support stress-triggered decompensation.
- reference: PMID:20823027
  title: Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
  findings:
  - statement: >-
      A 12-patient study linked severe disease and outcome to CSF HVA measures,
      reported hyperprolactinemia in severe cases, and described benefit from
      adjunctive selegiline in some patients.
    supporting_text: >-
      Hyperprolactinemia was found in 50% of the severe cases. Levodopa was the
      mainstay of treatment, and early addition of selegiline resulted in a
      remarkable response in some patients.
    evidence:
    - reference: PMID:20823027
      reference_title: Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Hyperprolactinemia was found in 50% of the severe cases. Levodopa was
        the mainstay of treatment, and early addition of selegiline resulted in
        a remarkable response in some patients.
      explanation: The cohort supports the endocrine signal and adjunctive treatment observation.
- reference: PMID:27830117
  title: "The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders."
  findings:
  - statement: >-
      iNTD provides an international longitudinal registry for natural history,
      diagnosis, treatment, genotype-phenotype, and quality-of-life data.
    supporting_text: >-
      The patient registry will enable detailed analysis of the natural courses
      of the diseases, the diagnostic approaches and the current therapy
      strategies as well as the quality of life of the affected patients and
      possible genotype/phenotype-correlations.
    evidence:
    - reference: PMID:27830117
      reference_title: "The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The patient registry will enable detailed analysis of the natural
        courses of the diseases, the diagnostic approaches and the current
        therapy strategies as well as the quality of life of the affected
        patients and possible genotype/phenotype-correlations.
      explanation: The registry publication defines the outcomes collected.
- reference: PMID:42141694
  title: "Cognitive and emotional experiences of parents of children with Tyrosine Hydroxylase Deficiency during the diagnostic journey in Serbia: A preliminary study."
  findings:
  - statement: >-
      A five-parent qualitative study identifies diagnostic uncertainty,
      communication challenges, and substantial emotional burden while noting
      limited geographic generalizability.
    supporting_text: >-
      We conducted semi-structured interviews with five parents of children
      diagnosed with Tyrosine Hydroxylase Deficiency.
    evidence:
    - reference: PMID:42141694
      reference_title: "Cognitive and emotional experiences of parents of children with Tyrosine Hydroxylase Deficiency during the diagnostic journey in Serbia: A preliminary study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We conducted semi-structured interviews with five parents of children
        diagnosed with Tyrosine Hydroxylase Deficiency.
      explanation: The qualitative study directly samples affected families.
- reference: PMID:34834538
  title: Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.
  found_in:
  - Autosomal_Recessive_Dopa_Responsive_Dystonia-deep-research-fallback.md
  findings:
  - statement: TH deficiency impairs catecholamine and dopamine synthesis.
    supporting_text: >-
      The expert review states that DRD is associated with defective dopamine
      synthesis and that TH catalyzes the rate-limiting step in catecholamine
      biosynthesis.
    evidence:
    - reference: PMID:34834538
      reference_title: Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        TH is a key enzyme that catalyzes the rate-limiting step in
        catecholamine biosynthesis, and THD patients often present with complex
        and variable phenotypes, which results in frequent misdiagnosis and lack
        of appropriate treatment.
      explanation: The expert review supports TH biochemistry and clinical heterogeneity.
- reference: PMID:9703425
  title: A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population.
  found_in:
  - Autosomal_Recessive_Dopa_Responsive_Dystonia-deep-research-fallback.md
  findings:
  - statement: Human mutation evidence links TH variants to autosomal recessive L-DOPA-responsive dystonia.
    supporting_text: >-
      The report identified homozygous TH R233H in three unrelated Dutch
      patients with autosomal recessive L-DOPA-responsive dystonia.
    evidence:
    - reference: PMID:9703425
      reference_title: A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This report concerns one new mutation in the tyrosine hydroxylase (TH)
        gene in three patients originating from three unrelated Dutch families
        with autosomal recessive L-DOPA-responsive dystonia (DRD).
      explanation: The human family study directly links TH to recessive DRD.
- reference: PMID:30383639
  title: "Compound heterozygous mutations in the TH gene in a Chinese family with autosomal-recessive dopa-responsive dystonia: A case report."
  found_in:
  - Autosomal_Recessive_Dopa_Responsive_Dystonia-deep-research-fallback.md
  findings:
  - statement: A Chinese case report supports TH compound heterozygosity, AR DRD symptoms, genetic diagnosis, and low-dose levodopa response.
    supporting_text: >-
      The abstract reports bradykinesia, dystonia, tremor, encephalopathy,
      compound heterozygous TH mutations, low-dose levodopa, and substantial
      dystonia improvement.
    evidence:
    - reference: PMID:30383639
      reference_title: "Compound heterozygous mutations in the TH gene in a Chinese family with autosomal-recessive dopa-responsive dystonia: A case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        RATIONALE: Autosomal-recessive dopa-responsive dystonia (DRD) is a rare
        clinical disorder presenting as bradykinesia, dystonia, tremor and even
        severe encephalopathy, and caused by tyrosine hydroxylase deficiency
        (THD).
      explanation: The case report directly supports the TH-deficient clinical spectrum.
- reference: PMID:20301681
  title: GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia.
  findings:
  - statement: >-
      GCH1-deficient DRD is an important phenotypic differential distinguished
      by heterozygous GCH1 disease and usually autosomal dominant inheritance.
    supporting_text: >-
      The diagnosis of GTPCH1-deficient DRD is established in a proband by
      identification of a heterozygous pathogenic variant in GCH1 by molecular
      genetic testing.
    evidence:
    - reference: PMID:20301681
      reference_title: GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The diagnosis of GTPCH1-deficient DRD is established in a proband by
        identification of a heterozygous pathogenic variant in GCH1 by
        molecular genetic testing.
      explanation: GeneReviews states the molecular distinction from biallelic TH disease.
- reference: PMID:19172410
  title: "Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up."
  findings:
  - statement: >-
      AADC deficiency has a distinct CSF signature with low HVA and 5-HIAA and
      elevated 3-O-methyldopa.
    supporting_text: >-
      In CSF all patients revealed the pattern typical of AADC with decreased
      concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated
      concentration of 3-ortho-methyldopa.
    evidence:
    - reference: PMID:19172410
      reference_title: "Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In CSF all patients revealed the pattern typical of AADC with decreased
        concentrations of homovanillic and 5-hydroxyindoleacetic acid and
        elevated concentration of 3-ortho-methyldopa.
      explanation: The cohort supports the biochemical differential from TH deficiency.
- reference: clinicaltrials:NCT03655223
  title: "Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns"
  findings:
  - statement: >-
      Early Check is a broad voluntary newborn-screening implementation study
      whose current condition panel includes autosomal recessive Segawa syndrome.
    supporting_text: >-
      Early Check provides voluntary screening of newborns for a selected panel
      of conditions.
    evidence:
    - reference: clinicaltrials:NCT03655223
      reference_title: "Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Early Check provides voluntary screening of newborns for a selected
        panel of conditions.
      explanation: The registry describes the broad newborn-screening program.
- reference: clinicaltrials:NCT05687474
  title: "Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect"
  findings:
  - statement: >-
      Baby Detect is a completed targeted-genomic newborn-screening program that
      included autosomal recessive Segawa syndrome among 126 conditions.
    supporting_text: >-
      Baby Detect Project is an innovative NBS program using a panel of target
      sequencing that aims to identify 126 treatable severe early onset genetic
      diseases at birth caused by 361 genes.
    evidence:
    - reference: clinicaltrials:NCT05687474
      reference_title: "Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Baby Detect Project is an innovative NBS program using a panel of target
        sequencing that aims to identify 126 treatable severe early onset
        genetic diseases at birth caused by 361 genes.
      explanation: The registry describes the targeted genomic newborn-screening program.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TH deficiency is inherited in an autosomal recessive manner."
    explanation: GeneReviews states autosomal recessive inheritance.
prevalence:
- population: Europe
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_low: 0.1
  rate_high: 0.9
  percentage: 1-9 / 1 000 000
  notes: Orphanet records European point prevalence in the one-to-nine per million range.
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| 1-9 / 1 000 000 | Europe | Point prevalence | ORPHANET |"
    explanation: Orphanet lists European point prevalence.
pathophysiology:
- name: Biallelic TH Loss of Function
  description: >-
    Biallelic pathogenic variants reduce TH catalytic activity, abundance, or
    stability. This impairs the tetrahydrobiopterin-dependent conversion of
    tyrosine to L-dopa, the rate-limiting step of catecholamine biosynthesis.
  genes:
  - preferred_term: TH
    term:
      id: hgnc:11782
      label: TH
  molecular_functions:
  - preferred_term: tyrosine 3-monooxygenase activity
    term:
      id: GO:0004511
      label: tyrosine 3-monooxygenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: catecholamine biosynthetic process
    term:
      id: GO:0042423
      label: catecholamine biosynthetic process
    modifier: DECREASED
  - preferred_term: dopamine biosynthetic process from tyrosine
    term:
      id: GO:0006585
      label: dopamine biosynthetic process from tyrosine
    modifier: DECREASED
  chemical_entities:
  - preferred_term: L-dopa
    term:
      id: CHEBI:15765
      label: L-dopa
    modifier: DECREASED
  downstream:
  - target: Cerebral Catecholamine Deficiency
    description: Reduced TH function limits CNS dopamine, norepinephrine, and epinephrine synthesis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41215497
      reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Autosomal recessive tyrosine hydroxylase deficiency (THD) leads to
        clinical phenotypes reflecting the deficiency of dopamine,
        norepinephrine, or epinephrine in the central nervous system (CNS),
        presenting along a continuous spectrum from mild to severe forms of the
        disease.
      explanation: The consensus directly links TH deficiency to CNS catecholamine deficiency.
  evidence:
  - reference: PMID:9703425
    reference_title: "A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This report concerns one new mutation in the tyrosine hydroxylase (TH)
      gene in three patients originating from three unrelated Dutch families
      with autosomal recessive L-DOPA-responsive dystonia (DRD).
    explanation: >-
      Human mutation evidence supports TH as a causative gene for autosomal
      recessive L-DOPA-responsive dystonia.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of TH deficiency is established in a proband by
      identification of biallelic pathogenic variants in TH by molecular genetic
      testing.
    explanation: >-
      GeneReviews supports biallelic TH pathogenic variants as the diagnostic
      molecular lesion.
  - reference: PMID:34834538
    reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TH is a key enzyme that catalyzes the rate-limiting step in catecholamine
      biosynthesis, and THD patients often present with complex and variable
      phenotypes, which results in frequent misdiagnosis and lack of appropriate
      treatment.
    explanation: >-
      Expert review supports the biochemical role of TH and links THD to the
      clinical spectrum.
  - reference: PMID:38196161
    reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Variants of the TH gene are associated with tyrosine hydroxylase
      deficiency (THD), a rare disorder with a wide phenotypic spectrum and
      variable response to treatment, which affects protein stability and may
      lead to accelerated degradation, loss of TH function and catecholamine
      deficiency.
    explanation: Patient-model work supports variant-dependent TH instability and loss of function.
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| TH | tyrosine hydroxylase | hgnc:11782 | Disease-causing germline mutation(s) in |"
    explanation: Orphanet lists TH as a disease-causing gene.
- name: Cerebral Catecholamine Deficiency
  description: >-
    Reduced TH flux lowers dopamine and other catecholamines in the CNS.
    Dopamine depletion is central to motor disease, while broader catecholamine
    loss contributes to autonomic and severe neurodevelopmental manifestations.
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  locations:
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  biological_processes:
  - preferred_term: dopamine biosynthetic process
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: dopamine
    term:
      id: CHEBI:18243
      label: dopamine
    modifier: DECREASED
  - preferred_term: noradrenaline
    term:
      id: CHEBI:18357
      label: (R)-noradrenaline
    modifier: DECREASED
  - preferred_term: adrenaline
    term:
      id: CHEBI:28918
      label: (R)-adrenaline
    modifier: DECREASED
  downstream:
  - target: Dopamine-Responsive Motor Circuit Dysfunction
    description: Dopamine depletion disrupts basal-ganglia motor control.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34834538
      reference_title: Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Dopa-responsive dystonia (DRD) is a rare movement disorder associated
        with defective dopamine synthesis.
      explanation: The review connects deficient dopamine synthesis to the movement disorder.
  - target: Infantile Catecholamine Deficiency Encephalopathy
    description: Severe early catecholamine deficiency disrupts motor and neurodevelopment.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        In individuals with TH-deficient progressive infantile encephalopathy,
        onset is before age three to six months.
      explanation: GeneReviews supports an early severe encephalopathy branch.
  - target: Autonomic Catecholamine Dysfunction
    description: Norepinephrine and epinephrine deficiency contributes to autonomic manifestations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41121981
      reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Movement disorders were present in 96.1% of cases, with developmental
        delay observed in 88.2%, and autonomic symptoms in 51.0%.
      explanation: The largest pediatric cohort documents frequent autonomic symptoms.
  - target: Stress-Triggered Neurologic Decompensation
    description: Infection or vaccination can precipitate episodic regression in a subset of patients.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - increased catecholamine demand during physiologic stress
    evidence:
    - reference: PMID:36101825
      reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        After viral infections or vaccination, she developed lethargy,
        worsened tremor, language, and motor regression including severe axial
        hypotonia, recuperating over several weeks of intensive rehabilitation
        but with residual tremor and mild lower limb spasticity.
      explanation: The report supports stress-associated neurologic decompensation.
  - target: Striatal Inhibitory Circuit Remodeling
    description: A knock-in model suggests circuit imbalance and compensatory plasticity.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:41872043
      reference_title: "Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Overall, our findings demonstrate that TH deficiency disrupts striatal
        inhibitory circuitry and triggers compensatory neuronal plasticity,
        without causing neuronal degeneration.
      explanation: The knock-in mouse supports an emerging circuit-remodeling branch.
  - target: Decreased CSF Homovanillic Acid
    description: Reduced dopamine synthesis lowers its CSF metabolite HVA.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41215497
      reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The diagnosis is suggested by the detection of low CSF homovanillic
        acid (HVA) and confirmed by identifying biallelic pathogenic variants
        in the TH gene.
      explanation: Low CSF HVA is the consensus biochemical readout.
  evidence:
  - reference: PMID:34834538
    reference_title: "Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Dopa-responsive dystonia (DRD) is a rare movement disorder associated
      with defective dopamine synthesis.
    explanation: Expert review links DRD to defective dopamine synthesis.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
      and signs (hypokinesia, rigidity of extremities, and/or tremor).
    explanation: >-
      GeneReviews links TH deficiency to parkinsonian motor signs downstream of
      dopamine synthesis impairment.
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Tyrosine hydroxylase (TH) catalyses the rate-limiting step in dopamine
      biosynthesis.
    explanation: The consensus supports the central biochemical defect.
- name: Dopamine-Responsive Motor Circuit Dysfunction
  description: >-
    Dopamine depletion in motor circuits produces dystonia, parkinsonism,
    hypokinesia, rigidity, tremor, ataxic gait, and oculogyric crises. The
    strong response of the mild phenotype to levodopa supports this functional
    rather than degenerative motor-circuit mechanism.
  locations:
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  downstream:
  - target: Limb Dystonia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        In individuals with TH-deficient dopa-responsive dystonia (DYT5b,
        DYT-TH), onset is between age 12 months and 12 years; initial symptoms
        are typically lower-limb dystonia and/or difficulty in walking.
      explanation: GeneReviews links TH deficiency to lower-limb dystonia.
  - target: Focal Dystonia
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0004373 | Focal dystonia | Frequent (79-30%) |"
      explanation: Orphanet records focal dystonia in this TH-deficiency entry.
  - target: Generalized Dystonia
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0007325 | Generalized dystonia | Occasional (29-5%) |"
      explanation: Orphanet records generalized dystonia.
  - target: Parkinsonism
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
        and signs (hypokinesia, rigidity of extremities, and/or tremor).
      explanation: GeneReviews supports parkinsonian motor manifestations.
  - target: Bradykinesia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30383639
      reference_title: "Compound heterozygous mutations in the TH gene in a Chinese family with autosomal-recessive dopa-responsive dystonia: A case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        RATIONALE: Autosomal-recessive dopa-responsive dystonia (DRD) is a rare
        clinical disorder presenting as bradykinesia, dystonia, tremor and even
        severe encephalopathy, and caused by tyrosine hydroxylase deficiency
        (THD).
      explanation: The clinical report connects TH deficiency to bradykinesia.
  - target: Hypokinesia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
        and signs (hypokinesia, rigidity of extremities, and/or tremor).
      explanation: GeneReviews supports hypokinesia.
  - target: Rigidity
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
        and signs (hypokinesia, rigidity of extremities, and/or tremor).
      explanation: GeneReviews supports limb rigidity.
  - target: Extrapyramidal Motor Dysfunction
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0002071 | Abnormality of extrapyramidal motor function | Frequent (79-30%) |"
      explanation: Orphanet records extrapyramidal motor dysfunction.
  - target: Postural Tremor
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0002174 | Postural tremor | Frequent (79-30%) |"
      explanation: Orphanet records postural tremor.
  - target: Myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - dopamine-depleted motor-network dysfunction
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0001336 | Myoclonus | Frequent (79-30%) |"
      explanation: Orphanet records myoclonus.
  - target: Ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0001251 | Ataxia | Frequent (79-30%) |"
      explanation: Orphanet records ataxia; the intermediary mechanism remains uncertain.
  - target: Gait Ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0002066 | Gait ataxia | Frequent (79-30%) |"
      explanation: Orphanet records gait ataxia; the intermediary mechanism remains uncertain.
  - target: Oculogyric Crisis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews supports oculogyric crises in severe TH deficiency.
  evidence:
  - reference: PMID:41121981
    reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Movement disorders were present in 96.1% of cases, with developmental delay observed in 88.2%, and autonomic symptoms in 51.0%."
    explanation: The pediatric cohort documents the near-universal movement-disorder burden.
- name: Infantile Catecholamine Deficiency Encephalopathy
  description: >-
    Severe early-onset TH deficiency can extend beyond focal dystonia to
    infantile parkinsonism and progressive infantile encephalopathy, with motor
    delay, hypotonia, ptosis, hyperreflexia, lethargy, irritability, excessive
    sweating, and drooling.
  downstream:
  - target: Motor Delay
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews directly supports marked motor delay.
  - target: Hypotonia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
        and signs (hypokinesia, rigidity of extremities, and/or tremor).
      explanation: GeneReviews directly supports infantile hypotonia.
  - target: Axial Hypotonia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36101825
      reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        After viral infections or vaccination, she developed lethargy,
        worsened tremor, language, and motor regression including severe axial
        hypotonia, recuperating over several weeks of intensive rehabilitation
        but with residual tremor and mild lower limb spasticity.
      explanation: A human case documents severe axial hypotonia.
  - target: Ptosis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews directly supports ptosis.
  - target: Brisk Reflexes
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0001348 | Brisk reflexes | Frequent (79-30%) |"
      explanation: Orphanet records brisk reflexes.
  - target: Lower Limb Hyperreflexia
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%) |"
      explanation: Orphanet records lower-limb hyperreflexia.
  - target: Babinski Sign
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal motor dysfunction in severe encephalopathy
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0003487 | Babinski sign | Frequent (79-30%) |"
      explanation: Orphanet records Babinski sign.
  - target: Mild Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews supports intellectual disability in severe disease.
  - target: Delayed Speech and Language Development
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - global neurodevelopmental impairment
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0000750 | Delayed speech and language development | Frequent (79-30%) |"
      explanation: Orphanet records speech and language delay.
  - target: Lethargy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews supports paroxysmal lethargy.
  - target: Irritability
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews supports irritability alternating with lethargy.
  - target: Feeding Difficulties
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - severe hypotonia and motor dysfunction
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0011968 | Feeding difficulties | Frequent (79-30%) |"
      explanation: Orphanet records feeding difficulties.
  - target: Pes Cavus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic lower-limb dystonia and abnormal muscle tone
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0001761 | Pes cavus | Frequent (79-30%) |"
      explanation: Orphanet records pes cavus.
  - target: Talipes Equinovarus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic lower-limb dystonia and abnormal muscle tone
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0001762 | Talipes equinovarus | Frequent (79-30%) |"
      explanation: Orphanet records talipes equinovarus.
  - target: Progressive Encephalopathy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        In individuals with TH-deficient progressive infantile encephalopathy,
        onset is before age three to six months.
      explanation: GeneReviews supports progressive infantile encephalopathy.
  evidence:
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In individuals with TH-deficient progressive infantile encephalopathy,
      onset is before age three to six months.
    explanation: GeneReviews supports very early onset in the severe phenotype.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Affected individuals have marked delay in motor development, truncal
      hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
      spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
      disability, and paroxysmal periods of lethargy (with increased sweating
      and drooling) alternating with irritability.
    explanation: >-
      GeneReviews supports the infantile encephalopathy clinical consequences.
- name: Autonomic Catecholamine Dysfunction
  description: >-
    Central catecholamine deficiency can produce sweating, drooling, and
    gastrointestinal dysmotility, especially in severe infantile disease.
  downstream:
  - target: Excessive Salivation
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Affected individuals have marked delay in motor development, truncal
        hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
        spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
        disability, and paroxysmal periods of lethargy (with increased sweating
        and drooling) alternating with irritability.
      explanation: GeneReviews supports drooling in severe disease.
  - target: Night Sweats
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0030166 | Night sweats | Frequent (79-30%) |"
      explanation: Orphanet records night sweats.
  - target: Constipation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - catecholamine-related autonomic dysmotility
    evidence:
    - reference: ORPHA:101150
      reference_title: Autosomal recessive dopa-responsive dystonia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "| HP:0002019 | Constipation | Frequent (79-30%) |"
      explanation: Orphanet records constipation.
  evidence:
  - reference: PMID:41121981
    reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Movement disorders were present in 96.1% of cases, with developmental delay observed in 88.2%, and autonomic symptoms in 51.0%."
    explanation: The largest pediatric cohort documents autonomic manifestations in about half.
- name: Stress-Triggered Neurologic Decompensation
  description: >-
    A subset of patients can develop episodic lethargy, worsened tremor,
    language and motor regression, and axial hypotonia after infection or
    vaccination, with recovery over weeks and prevention of recurrence after
    levodopa/carbidopa in the reported cases.
  downstream:
  - target: Lethargy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36101825
      reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        After viral infections or vaccination, she developed lethargy,
        worsened tremor, language, and motor regression including severe axial
        hypotonia, recuperating over several weeks of intensive rehabilitation
        but with residual tremor and mild lower limb spasticity.
      explanation: The human report directly links physiologic stress to lethargic episodes.
  - target: Axial Hypotonia
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36101825
      reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        After viral infections or vaccination, she developed lethargy,
        worsened tremor, language, and motor regression including severe axial
        hypotonia, recuperating over several weeks of intensive rehabilitation
        but with residual tremor and mild lower limb spasticity.
      explanation: The human report directly supports stress-associated axial hypotonia.
  evidence:
  - reference: PMID:36101825
    reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Literature review revealed four other THD patients who had a total of
      seven episodes of marked hypotonia and motor regression following
      infections, occurring between ages 12 months and 6 years.
    explanation: The report extends the episodic presentation beyond one patient.
- name: Striatal Inhibitory Circuit Remodeling
  description: >-
    In the Th-p.R203H knock-in mouse, regionally reduced TH without reduced
    Th transcript or dopaminergic neuronal loss is associated with impaired TH
    axonal transport, altered striatal GABAergic interneuron TH expression, and
    compensatory neuronal plasticity. This is an emerging model-derived
    mechanism, not yet established as a universal human disease feature.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: axonal transport
    term:
      id: GO:0098930
      label: axonal transport
    modifier: DECREASED
  - preferred_term: regulation of neuronal synaptic plasticity
    term:
      id: GO:0048168
      label: regulation of neuronal synaptic plasticity
    modifier: DYSREGULATED
  downstream:
  - target: Dopamine-Responsive Motor Circuit Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:41872043
      reference_title: "Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Overall, our findings demonstrate that TH deficiency disrupts striatal
        inhibitory circuitry and triggers compensatory neuronal plasticity,
        without causing neuronal degeneration.
      explanation: The knock-in mouse links circuit remodeling to motor-network dysfunction.
  evidence:
  - reference: PMID:41872043
    reference_title: "Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      No changes were observed in Th-mRNA expression, and the decreased level
      of TH in the concrete brain areas in Th-ki mice appears to be due to
      defective TH protein axonal transport.
    explanation: The model directly supports defective axonal delivery of TH protein.
phenotypes:
- category: Ophthalmologic
  name: Ptosis
  description: Ptosis is frequent in the severe TH deficiency spectrum.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0000508 | Ptosis | Frequent (79-30%) |"
    explanation: Orphanet lists ptosis as frequent.
- category: Neurologic
  name: Irritability
  description: Irritability is frequent and may alternate with lethargic episodes.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0000737 | Irritability | Frequent (79-30%) |"
    explanation: Orphanet lists irritability as frequent.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Affected individuals have marked delay in motor development, truncal
      hypotonia, severe hypokinesia, limb hypertonia (rigidity and/or
      spasticity), hyperreflexia, oculogyric crises, ptosis, intellectual
      disability, and paroxysmal periods of lethargy (with increased sweating
      and drooling) alternating with irritability.
    explanation: GeneReviews supports irritability in severe TH deficiency.
- category: Developmental
  name: Delayed Speech and Language Development
  description: Delayed speech and language development is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0000750 | Delayed speech and language development | Frequent
      (79-30%) |
    explanation: >-
      Orphanet lists delayed speech and language development as frequent.
- category: Neurologic
  name: Ataxia
  description: Ataxia is a frequent neurologic feature.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001251 | Ataxia | Frequent (79-30%) |"
    explanation: Orphanet lists ataxia as frequent.
- category: Neurologic
  name: Hypotonia
  description: Hypotonia is frequent, especially in infantile TH deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001252 | Hypotonia | Frequent (79-30%) |"
    explanation: Orphanet lists hypotonia as frequent.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
      and signs (hypokinesia, rigidity of extremities, and/or tremor).
    explanation: >-
      GeneReviews directly supports hypotonia in the infantile TH deficiency
      spectrum.
- category: Neurologic
  name: Lethargy
  description: Lethargy is frequent in severe TH deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001254 | Lethargy | Frequent (79-30%) |"
    explanation: Orphanet lists lethargy as frequent.
- category: Neurologic
  name: Mild Intellectual Disability
  description: Mild intellectual disability is reported occasionally.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Mild intellectual disability
    term:
      id: HP:0001256
      label: Mild intellectual disability
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001256 | Intellectual disability, mild | Occasional (29-5%) |"
    explanation: Orphanet lists mild intellectual disability as occasional.
- category: Neurologic
  name: Motor Delay
  description: Motor delay is frequent in the infantile forms.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001270 | Motor delay | Frequent (79-30%) |"
    explanation: Orphanet lists motor delay as frequent.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In contrast to TH-deficient DRD, motor milestones are overtly delayed in
      this severe form.
    explanation: GeneReviews supports motor delay in severe TH deficiency.
- category: Neurologic
  name: Axial Hypotonia
  description: >-
    Truncal or axial hypotonia is characteristic of infantile TH deficiency and
    can become severe during episodic decompensation.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Axial hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  evidence:
  - reference: PMID:20301610
    reference_title: Tyrosine Hydroxylase Deficiency.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Affected infants demonstrate truncal hypotonia and parkinsonian symptoms
      and signs (hypokinesia, rigidity of extremities, and/or tremor).
    explanation: GeneReviews directly supports axial/truncal hypotonia.
  - reference: PMID:36101825
    reference_title: "Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After viral infections or vaccination, she developed lethargy, worsened
      tremor, language, and motor regression including severe axial hypotonia,
      recuperating over several weeks of intensive rehabilitation but with
      residual tremor and mild lower limb spasticity.
    explanation: A human case documents severe axial hypotonia during decompensation.
- category: Neurologic
  name: Parkinsonism
  description: Parkinsonism is frequent, particularly in infantile motor-delay cases.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001300 | Parkinsonism | Frequent (79-30%) |"
    explanation: Orphanet lists parkinsonism as frequent.
- category: Neurologic
  name: Myoclonus
  description: Myoclonus is a frequent movement feature.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001336 | Myoclonus | Frequent (79-30%) |"
    explanation: Orphanet lists myoclonus as frequent.
- category: Neurologic
  name: Brisk Reflexes
  description: Brisk reflexes and hyperreflexia are frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Brisk reflexes
    term:
      id: HP:0001348
      label: Brisk reflexes
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001348 | Brisk reflexes | Frequent (79-30%) |"
    explanation: Orphanet lists brisk reflexes as frequent.
- category: Musculoskeletal
  name: Pes Cavus
  description: Pes cavus is a frequent foot phenotype.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Pes cavus
    term:
      id: HP:0001761
      label: Pes cavus
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001761 | Pes cavus | Frequent (79-30%) |"
    explanation: Orphanet lists pes cavus as frequent.
- category: Musculoskeletal
  name: Talipes Equinovarus
  description: Talipes equinovarus is a frequent foot posture abnormality.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Talipes equinovarus
    term:
      id: HP:0001762
      label: Talipes equinovarus
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0001762 | Talipes equinovarus | Frequent (79-30%) |"
    explanation: Orphanet lists talipes equinovarus as frequent.
- category: Gastrointestinal
  name: Constipation
  description: Constipation is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002019 | Constipation | Frequent (79-30%) |"
    explanation: Orphanet lists constipation as frequent.
- category: Neurologic
  name: Rigidity
  description: Rigidity is a frequent parkinsonian sign.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002063 | Rigidity | Frequent (79-30%) |"
    explanation: Orphanet lists rigidity as frequent.
- category: Neurologic
  name: Gait Ataxia
  description: Gait ataxia is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Gait ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002066 | Gait ataxia | Frequent (79-30%) |"
    explanation: Orphanet lists gait ataxia as frequent.
- category: Neurologic
  name: Bradykinesia
  description: Bradykinesia is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002067 | Bradykinesia | Frequent (79-30%) |"
    explanation: Orphanet lists bradykinesia as frequent.
  - reference: PMID:30383639
    reference_title: "Compound heterozygous mutations in the TH gene in a Chinese family with autosomal-recessive dopa-responsive dystonia: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RATIONALE: Autosomal-recessive dopa-responsive dystonia (DRD) is a rare
      clinical disorder presenting as bradykinesia, dystonia, tremor and even
      severe encephalopathy, and caused by tyrosine hydroxylase deficiency
      (THD).
    explanation: Case-report abstract supports bradykinesia in AR DRD.
- category: Neurologic
  name: Extrapyramidal Motor Dysfunction
  description: Extrapyramidal motor dysfunction is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormality of extrapyramidal motor function
    term:
      id: HP:0002071
      label: Abnormality of extrapyramidal motor function
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0002071 | Abnormality of extrapyramidal motor function | Frequent
      (79-30%) |
    explanation: Orphanet lists abnormal extrapyramidal motor function as frequent.
- category: Neurologic
  name: Postural Tremor
  description: Postural tremor is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Postural tremor
    term:
      id: HP:0002174
      label: Postural tremor
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002174 | Postural tremor | Frequent (79-30%) |"
    explanation: Orphanet lists postural tremor as frequent.
- category: Neurologic
  name: Hypokinesia
  description: Hypokinesia is frequent in the parkinsonian TH deficiency spectrum.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypokinesia
    term:
      id: HP:0002375
      label: Hypokinesia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002375 | Hypokinesia | Frequent (79-30%) |"
    explanation: Orphanet lists hypokinesia as frequent.
- category: Neurologic
  name: Lower Limb Hyperreflexia
  description: Lower limb hyperreflexia is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Lower limb hyperreflexia
    term:
      id: HP:0002395
      label: Lower limb hyperreflexia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002395 | Lower limb hyperreflexia | Frequent (79-30%) |"
    explanation: Orphanet lists lower limb hyperreflexia as frequent.
- category: Neurologic
  name: Progressive Encephalopathy
  description: Progressive encephalopathy is reported very rarely in the severe spectrum.
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Progressive encephalopathy
    term:
      id: HP:0002448
      label: Progressive encephalopathy
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002448 | Progressive encephalopathy | Very rare (<4-1%) |"
    explanation: Orphanet lists progressive encephalopathy as very rare.
- category: Neurologic
  name: Limb Dystonia
  description: Limb dystonia is frequent and often begins in the lower limbs.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Limb dystonia
    term:
      id: HP:0002451
      label: Limb dystonia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0002451 | Limb dystonia | Frequent (79-30%) |"
    explanation: Orphanet lists limb dystonia as frequent.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In individuals with TH-deficient dopa-responsive dystonia (DYT5b, DYT-TH),
      onset is between age 12 months and 12 years; initial symptoms are
      typically lower-limb dystonia and/or difficulty in walking.
    explanation: GeneReviews supports lower-limb dystonia as a typical initial symptom.
- category: Neurologic
  name: Babinski Sign
  description: Babinski sign is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Babinski sign
    term:
      id: HP:0003487
      label: Babinski sign
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0003487 | Babinski sign | Frequent (79-30%) |"
    explanation: Orphanet lists Babinski sign as frequent.
- category: Autonomic
  name: Excessive Salivation
  description: Excessive salivation and drooling are frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Excessive salivation
    term:
      id: HP:0003781
      label: Excessive salivation
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0003781 | Excessive salivation | Frequent (79-30%) |"
    explanation: Orphanet lists excessive salivation as frequent.
- category: Biochemical
  name: Decreased CSF Homovanillic Acid
  description: >-
    Decreased CSF homovanillic acid reflects impaired central dopamine
    metabolism and is listed as frequent by Orphanet.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Decreased CSF homovanillic acid concentration
    term:
      id: HP:0003785
      label: Decreased CSF homovanillic acid concentration
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      | HP:0003785 | Decreased CSF homovanillic acid concentration | Frequent
      (79-30%) |
    explanation: >-
      Orphanet lists decreased CSF homovanillic acid concentration as frequent.
- category: Neurologic
  name: Focal Dystonia
  description: Focal dystonia is frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Focal dystonia
    term:
      id: HP:0004373
      label: Focal dystonia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0004373 | Focal dystonia | Frequent (79-30%) |"
    explanation: Orphanet lists focal dystonia as frequent.
- category: Neurologic
  name: Generalized Dystonia
  description: Generalized dystonia is reported occasionally.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Generalized dystonia
    term:
      id: HP:0007325
      label: Generalized dystonia
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0007325 | Generalized dystonia | Occasional (29-5%) |"
    explanation: Orphanet lists generalized dystonia as occasional.
- category: Neurologic
  name: Oculogyric Crisis
  description: Oculogyric crises are frequent in severe early-onset TH deficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Oculogyric crisis
    term:
      id: HP:0010553
      label: Oculogyric crisis
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0010553 | Oculogyric crisis | Frequent (79-30%) |"
    explanation: Orphanet lists oculogyric crisis as frequent.
- category: Gastrointestinal
  name: Feeding Difficulties
  description: Feeding difficulties are frequent in the infantile disease spectrum.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0011968 | Feeding difficulties | Frequent (79-30%) |"
    explanation: Orphanet lists feeding difficulties as frequent.
- category: Autonomic
  name: Night Sweats
  description: Night sweats are frequent.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Night sweats
    term:
      id: HP:0030166
      label: Night sweats
  evidence:
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| HP:0030166 | Night sweats | Frequent (79-30%) |"
    explanation: Orphanet lists night sweats as frequent.
biochemical:
- name: Low CSF homovanillic acid
  biomarker_term:
    preferred_term: homovanillic acid
    term:
      id: CHEBI:545959
      label: homovanillic acid
  presence: DECREASED
  notes: >-
    Low CSF homovanillic acid is a neurotransmitter-metabolite clue to central
    dopamine synthesis impairment. The consensus guideline treats it as a
    diagnostic suggestion, not a substitute for biallelic TH confirmation.
  readouts:
  - target: Cerebral Catecholamine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Reduced CSF HVA reports reduced central dopamine turnover.
    evidence:
    - reference: PMID:20430833
      reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Decreased cerebrospinal fluid concentrations of homovanillic acid and
        3-methoxy-4-hydroxyphenylethylene glycol, with normal
        5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
        biochemical hallmark of tyrosine hydroxylase deficiency.
      explanation: The clinical study establishes low HVA as a disease readout.
  evidence:
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis is suggested by the detection of low CSF homovanillic acid
      (HVA) and confirmed by identifying biallelic pathogenic variants in the
      TH gene.
    explanation: The consensus identifies low CSF HVA as the key biochemical clue.
  - reference: PMID:20430833
    reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Decreased cerebrospinal fluid concentrations of homovanillic acid and
      3-methoxy-4-hydroxyphenylethylene glycol, with normal
      5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
      biochemical hallmark of tyrosine hydroxylase deficiency.
    explanation: The 36-patient study establishes the characteristic CSF pattern.
- name: Low CSF 3-methoxy-4-hydroxyphenylethylene glycol
  biomarker_term:
    preferred_term: 3-Methoxy-4-hydroxyphenylethyleneglycol
    term:
      id: CHEBI:1576
      label: 3-Methoxy-4-hydroxyphenylethyleneglycol
  presence: DECREASED
  notes: >-
    Low CSF MHPG reflects reduced central norepinephrine turnover and
    complements low HVA in the characteristic TH-deficiency profile.
  readouts:
  - target: Cerebral Catecholamine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Reduced CSF MHPG reports reduced central norepinephrine turnover.
    evidence:
    - reference: PMID:20430833
      reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Decreased cerebrospinal fluid concentrations of homovanillic acid and
        3-methoxy-4-hydroxyphenylethylene glycol, with normal
        5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
        biochemical hallmark of tyrosine hydroxylase deficiency.
      explanation: The clinical study establishes low MHPG as a disease readout.
  evidence:
  - reference: PMID:20430833
    reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Decreased cerebrospinal fluid concentrations of homovanillic acid and
      3-methoxy-4-hydroxyphenylethylene glycol, with normal
      5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
      biochemical hallmark of tyrosine hydroxylase deficiency.
    explanation: The clinical study establishes decreased CSF MHPG.
- name: Normal CSF 5-hydroxyindoleacetic acid
  biomarker_term:
    preferred_term: 5-hydroxyindoleacetic acid
    term:
      id: CHEBI:27823
      label: (5-hydroxyindol-3-yl)acetic acid
  presence: NORMAL
  notes: >-
    Preserved CSF 5-HIAA distinguishes the predominantly catecholaminergic TH
    block from disorders that also impair serotonin synthesis, especially AADC
    and several BH4-pathway deficiencies.
  evidence:
  - reference: PMID:20430833
    reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Decreased cerebrospinal fluid concentrations of homovanillic acid and
      3-methoxy-4-hydroxyphenylethylene glycol, with normal
      5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
      biochemical hallmark of tyrosine hydroxylase deficiency.
    explanation: The clinical study establishes normal CSF 5-HIAA as part of the signature.
genetic:
- name: TH biallelic pathogenic variants
  gene_term:
    preferred_term: TH
    term:
      id: hgnc:11782
      label: TH
  association: Causative biallelic loss-of-function pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >-
    Missense, nonsense, promoter, and other pathogenic alleles reduce TH
    activity or protein abundance. Phenotype and levodopa-dose requirements
    vary by allelic combination; the common p.R233H allele does not by itself
    define a uniform severity.
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:20301610
      reference_title: "Tyrosine Hydroxylase Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "TH deficiency is inherited in an autosomal recessive manner."
      explanation: GeneReviews supports autosomal recessive inheritance.
  evidence:
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of TH deficiency is established in a proband by
      identification of biallelic pathogenic variants in TH by molecular genetic
      testing.
    explanation: Supports biallelic TH pathogenic variants as diagnostic.
  - reference: ORPHA:101150
    reference_title: "Autosomal recessive dopa-responsive dystonia"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| TH | tyrosine hydroxylase | hgnc:11782 | Disease-causing germline mutation(s) in |"
    explanation: Orphanet lists TH as a disease-causing gene.
  - reference: PMID:41121981
    reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among the 36 identified variants, the predominant were p.R233H (37.3%),
      p.R153X (10.8%), and p.Q232X (6.9%).
    explanation: The large pediatric cohort documents recurrent missense and nonsense alleles.
diagnosis:
- name: Molecular genetic testing
  presence: Positive
  description: >-
    Confirm TH deficiency by identifying pathogenic or likely pathogenic
    variants on both TH alleles. Molecular confirmation is essential because
    the phenotype overlaps several dopamine and BH4 pathway disorders.
  evidence:
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis is suggested by the detection of low CSF homovanillic acid
      (HVA) and confirmed by identifying biallelic pathogenic variants in the
      TH gene.
    explanation: The current consensus requires biallelic TH confirmation.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of TH deficiency is established in a proband by
      identification of biallelic pathogenic variants in TH by molecular genetic
      testing.
    explanation: GeneReviews supports molecular genetic testing for TH deficiency.
- name: CSF neurotransmitter metabolite testing
  presence: Positive
  description: >-
    The characteristic pretreatment pattern is low HVA and MHPG with normal
    5-HIAA. HVA and the HVA/5-HIAA ratio can correlate with severity, but
    age-adjusted sampling and molecular confirmation are required.
  evidence:
  - reference: PMID:20430833
    reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Decreased cerebrospinal fluid concentrations of homovanillic acid and
      3-methoxy-4-hydroxyphenylethylene glycol, with normal
      5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
      biochemical hallmark of tyrosine hydroxylase deficiency.
    explanation: The clinical cohort defines the distinguishing CSF pattern.
  - reference: PMID:33996491
    reference_title: Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study confirms that cerebrospinal fluid is the most informative body
      fluid to measure monoamine neurotransmitter metabolites when AADC or TH
      deficiency is suspected, and that routine follow-up of cerebrospinal
      fluid measurements to estimate treatment response is not needed.
    explanation: This study supports CSF for diagnosis but not routine response monitoring.
- name: Levodopa responsiveness
  presence: Supportive but not required
  description: >-
    A marked, sustained response strongly supports a dopamine-synthesis
    disorder, especially in mild TH-deficient DRD. Incomplete response or
    dose-limiting dyskinesia in severe disease does not exclude TH deficiency.
  evidence:
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      All individuals with TH-deficient DRD demonstrate complete responsiveness
      of symptoms to levodopa (with a decarboxylase inhibitor).
    explanation: GeneReviews supports levodopa responsiveness in the mild subtype.
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, initiation of therapy can be challenging in patients with severe
      disease forms who develop L-dopa/DCI-induced dyskinesia.
    explanation: The consensus cautions that severe disease may have treatment-limiting dyskinesia.
- name: Peripheral monoamine metabolite testing
  presence: Not exclusionary
  description: >-
    Normal urine or blood catecholamine metabolites do not rule out TH
    deficiency. Peripheral measurements are less informative than CSF, and
    urinary dopamine is often normal despite the central metabolic block.
  evidence:
  - reference: PMID:33996491
    reference_title: Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, in many patients with TH or AADC deficiency dopamine in urine is
      normal or increased thereby not reflecting the metabolic block.
    explanation: Normal or increased urinary dopamine cannot exclude TH deficiency.
differential_diagnoses:
- name: GTP cyclohydrolase 1-deficient dopa-responsive dystonia
  disease_term:
    preferred_term: autosomal dominant dopa-responsive dystonia
    term:
      id: MONDO:0971063
      label: autosomal dominant dopa-responsive dystonia
  description: >-
    GCH1-deficient DRD shares childhood dystonia, diurnal fluctuation, and a
    dramatic levodopa response with mild TH deficiency.
  distinguishing_features:
  - Usually a heterozygous GCH1 disorder with autosomal dominant inheritance and reduced penetrance
  - Intellectual, cerebellar, and autonomic manifestations generally do not occur in classic GCH1-deficient DRD
  - Molecular testing identifies GCH1 rather than biallelic TH variants
  evidence:
  - reference: PMID:20301681
    reference_title: GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The diagnosis of GTPCH1-deficient DRD is established in a proband by
      identification of a heterozygous pathogenic variant in GCH1 by molecular
      genetic testing.
    explanation: GeneReviews provides the decisive molecular distinction.
  - reference: PMID:20301681
    reference_title: GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Intellectual, cerebellar, sensory, and autonomic disturbances generally
      do not occur.
    explanation: This contrasts classic GCH1 disease with severe TH-deficiency manifestations.
- name: Sepiapterin reductase deficiency
  description: >-
    Biallelic SPR disease is another recessive, levodopa-responsive
    neurotransmitter disorder and can present with dystonia, developmental
    impairment, oculogyric crises, and diurnal fluctuation.
  distinguishing_features:
  - Biallelic SPR rather than TH variants
  - BH4-pathway dysfunction can reduce serotonin as well as catecholamine synthesis
  - The TH-deficiency hallmark retains normal CSF 5-HIAA
  evidence:
  - reference: PMID:34834538
    reference_title: Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This impairment may be due to the fact of a deficiency in GTP
      cyclohydrolase I (GTPCHI, GCH1 gene), sepiapterin reductase (SR), tyrosine
      hydroxylase (TH), or 6-pyruvoyl tetrahydrobiopterin synthase (PTPS) enzyme
      functions.
    explanation: The review places SPR and TH defects within the DRD differential.
  - reference: PMID:20430833
    reference_title: "Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Decreased cerebrospinal fluid concentrations of homovanillic acid and
      3-methoxy-4-hydroxyphenylethylene glycol, with normal
      5-hydroxyindoleacetic acid cerebrospinal fluid concentrations, are the
      biochemical hallmark of tyrosine hydroxylase deficiency.
    explanation: Normal CSF 5-HIAA supports TH rather than a combined monoamine defect.
- name: Aromatic L-amino acid decarboxylase deficiency
  disease_term:
    preferred_term: aromatic L-amino acid decarboxylase deficiency
    term:
      id: MONDO:0012084
      label: aromatic L-amino acid decarboxylase deficiency
  description: >-
    AADC deficiency overlaps with severe TH deficiency through early hypotonia,
    developmental delay, dystonia, oculogyric crises, and autonomic dysfunction.
  distinguishing_features:
  - Biallelic DDC rather than TH variants
  - Low CSF HVA and 5-HIAA with elevated 3-O-methyldopa, rather than normal 5-HIAA
  - Peripheral 3-O-methyldopa is a promising AADC marker but not a TH-deficiency marker
  evidence:
  - reference: PMID:19172410
    reference_title: "Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In CSF all patients revealed the pattern typical of AADC with decreased
      concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated
      concentration of 3-ortho-methyldopa.
    explanation: The AADC CSF profile differs from the normal 5-HIAA of TH deficiency.
  - reference: PMID:33996491
    reference_title: Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3-O-methyldopa in dried blood spots and vanillactic acid in urine are
      promising peripheral biomarkers for diagnosis of AADC deficiency.
    explanation: The peripheral markers help distinguish AADC from TH deficiency.
- name: Cerebral palsy and static motor disorders
  description: >-
    Infantile hypotonia, spasticity, dystonia, motor delay, and normal or
    nonspecific imaging can lead to a cerebral-palsy label. Diurnal fluctuation,
    episodic regression, CSF neurotransmitter abnormalities, and biallelic TH
    variants establish a treatable metabolic disorder instead.
  distinguishing_features:
  - Diurnal fluctuation or episodic decompensation
  - Low CSF HVA and MHPG with normal 5-HIAA
  - Biallelic pathogenic TH variants and a levodopa response
  evidence:
  - reference: PMID:27830117
    reference_title: "The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As a consequence, patients and their parents often traverse a stressful
      odyssey from doctor to doctor with frequent misdiagnoses, such as cerebral
      palsy, myasthenia gravis or seizure disorders
    explanation: The registry-network report identifies cerebral palsy as a frequent misdiagnosis.
treatments:
- name: Severity-adapted levodopa with a decarboxylase inhibitor
  description: >-
    Levodopa plus carbidopa or another peripheral decarboxylase inhibitor
    bypasses the TH block and is first-line therapy. Start low and titrate
    dynamically: mild DRD usually responds completely, infantile parkinsonism
    often improves incompletely and slowly, and severe encephalopathy may be
    extremely sensitive with dose-limiting dyskinesia.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
    - preferred_term: carbidopa
      term:
        id: CHEBI:3395
        label: carbidopa
  target_phenotypes:
  - preferred_term: Limb dystonia
    term:
      id: HP:0002451
      label: Limb dystonia
  - preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  - preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  target_mechanisms:
  - target: Biallelic TH Loss of Function
    treatment_effect: BYPASSES
    evidence:
    - reference: PMID:41215497
      reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        L-dopa/decarboxylase inhibitor (DCI) supplementation is often the
        first-line treatment, and most patients have a good therapeutic
        response.
      explanation: Levodopa supplies the product downstream of the impaired TH step.
  - target: Cerebral Catecholamine Deficiency
    treatment_effect: RESTORES
    evidence:
    - reference: PMID:20301610
      reference_title: Tyrosine Hydroxylase Deficiency.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        All individuals with TH-deficient DRD demonstrate complete
        responsiveness of symptoms to levodopa (with a decarboxylase inhibitor).
      explanation: Clinical response supports functional restoration of dopamine supply.
  evidence:
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      L-dopa/decarboxylase inhibitor (DCI) supplementation is often the
      first-line treatment, and most patients have a good therapeutic response.
    explanation: The current consensus identifies levodopa/DCI as first-line therapy.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      All individuals with TH-deficient DRD demonstrate complete responsiveness
      of symptoms to levodopa (with a decarboxylase inhibitor).
    explanation: GeneReviews supports levodopa with a decarboxylase inhibitor for TH-deficient DRD.
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Individuals with TH-deficient infantile parkinsonism with motor delay
      demonstrate a marked response to levodopa.
    explanation: GeneReviews supports marked levodopa response in the severe motor-delay subtype.
  - reference: PMID:41121981
    reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variant type-particularly R233H/nonsense versus R233H/missense
      significantly influences dose requirements, underscoring the value of
      genotype-guided, dynamic levodopa titration to optimize long-term outcomes.
    explanation: The pediatric cohort supports dynamic, genotype-informed dose adjustment.
- name: Monoamine oxidase inhibitor adjunct
  description: >-
    Selegiline or another monoamine oxidase inhibitor may be considered by a
    specialist when levodopa alone gives inadequate control or severe disease
    limits titration. Evidence is limited to small observational experience;
    the consensus explicitly calls for further evaluation.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: selegiline
      term:
        id: CHEBI:50217
        label: selegiline
  target_phenotypes:
  - preferred_term: Limb dystonia
    term:
      id: HP:0002451
      label: Limb dystonia
  - preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  target_mechanisms:
  - target: Cerebral Catecholamine Deficiency
    treatment_effect: MODULATES
    evidence:
    - reference: PMID:20823027
      reference_title: Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Levodopa was the mainstay of treatment, and early addition of selegiline
        resulted in a remarkable response in some patients.
      explanation: Selegiline can augment catecholaminergic treatment in selected patients.
  evidence:
  - reference: PMID:20823027
    reference_title: Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Levodopa was the mainstay of treatment, and early addition of selegiline
      resulted in a remarkable response in some patients.
    explanation: A small human series reports adjunctive benefit in some patients.
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Therefore, alternative treatment options, such as monoamine oxidase (MAO)
      inhibitors, must be evaluated to optimize motor symptom control.
    explanation: The consensus identifies MAO inhibitors as an option requiring further evaluation.
- name: Multidisciplinary developmental and supportive care
  description: >-
    Movement-disorder follow-up, neurodevelopmental surveillance, physical and
    occupational therapy, speech/feeding support, nutrition, and management of
    comorbidities complement pharmacotherapy, especially when severe deficits
    persist.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Additionally, a multidisciplinary treatment approach should be utilized
      to monitor neurocognitive development and other comorbidities that may
      occur in THD.
    explanation: The consensus recommends multidisciplinary monitoring and care.
- name: Avoid antidopaminergic agents
  description: >-
    The prokinetic agent metoclopramide (Reglan) and other related
    antidopaminergic agents should be avoided because they can acutely
    worsen the dopamine deficiency that underlies TH-deficient
    dopa-responsive dystonia.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301610
    reference_title: "Tyrosine Hydroxylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Agents/circumstances to avoid: The prokinetic agent Reglan® and other related antidopaminergic agents."
    explanation: >-
      GeneReviews explicitly lists the prokinetic agent metoclopramide
      (Reglan) and other related antidopaminergic agents as agents to avoid
      in tyrosine hydroxylase deficiency, since they can exacerbate the
      underlying dopamine deficit.
clinical_trials:
- name: NCT03655223
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Early Check is a broad voluntary newborn-screening implementation study in
    North and South Carolina. Its current condition panel includes autosomal
    recessive Segawa syndrome; it is not a TH-deficiency treatment trial.
  evidence:
  - reference: clinicaltrials:NCT03655223
    reference_title: "Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early Check provides voluntary screening of newborns for a selected panel
      of conditions.
    explanation: The registry record defines the newborn-screening design.
  notes: >-
    ClinicalTrials.gov condition list and status checked 2026-07-23. The search
    found no disease-specific interventional TH-deficiency trial.
- name: NCT05687474
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    Baby Detect evaluated targeted genomic newborn screening in
    Wallonia-Brussels for 126 treatable severe early-onset genetic diseases,
    including autosomal recessive Segawa syndrome. It was a screening program,
    not a therapeutic trial.
  evidence:
  - reference: clinicaltrials:NCT05687474
    reference_title: "Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Baby Detect Project is an innovative NBS program using a panel of target
      sequencing that aims to identify 126 treatable severe early onset genetic
      diseases at birth caused by 361 genes.
    explanation: The registry record defines the completed targeted genomic screening program.
  notes: ClinicalTrials.gov condition list and status checked 2026-07-23.
animal_models:
- species: Mus musculus
  genotype: Th-p.R203H knock-in mouse corresponding to human TH p.R202H/p.R233H disease nomenclature
  genes:
  - preferred_term: Th
    term:
      id: MGI:98735
      label: Th
  description: >-
    This knock-in model has reduced TH and dopamine across several brain
    regions, motor impairment, defective TH protein axonal transport, altered
    striatal interneuron markers, and compensatory plasticity without
    dopaminergic neuronal degeneration. BH4 improved motor outcomes in
    preclinical treatment experiments.
  associated_phenotypes:
  - Reduced brain TH and dopamine
  - Motor impairment and catalepsy
  - Altered striatal inhibitory circuitry
  - Compensatory neuronal plasticity without dopaminergic neuron loss
  evidence:
  - reference: PMID:41872043
    reference_title: "Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Th-ki mice displayed significantly reduced TH, especially in the
      striatum, but also in the cortex, olfactory bulb, cerebellum, substantia
      nigra, globus pallidus, and spinal cord, a decrease that is not associated
      with dopaminergic neuronal degeneration.
    explanation: The knock-in mouse recapitulates regional TH deficiency without neuron loss.
  - reference: PMID:38196161
    reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Importantly, treatment with BH4 significantly improved motor function in
      these mice, as demonstrated by increased latency on the rotarod test and
      improved horizontal activity (catalepsy).
    explanation: BH4 produces preclinical motor rescue in the knock-in model.
experimental_models:
- name: Patient-derived THD iPSC dopaminergic neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: >-
    Patient-derived induced pluripotent stem cells differentiated into
    dopaminergic neurons, with healthy and gene-corrected isogenic controls
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  conditions:
  - Mild levodopa-responsive THD-A genotypes
  - Severe THD-B genotypes with poor post-differentiation levodopa response
  - Healthy and gene-corrected isogenic controls
  publication: PMID:36740977
  description: >-
    Patient-derived neurons reproduce reduced TH and dopamine metabolites,
    shortened neurites, and reduced arborization. Levodopa rescued mature
    THD-A neurons, while precursor-stage treatment prevented defects in THD-B,
    suggesting phenotype-specific response and a possible developmental window.
  modeled_mechanisms:
  - target: Biallelic TH Loss of Function
    description: Patient neurons model reduced TH abundance caused by biallelic disease alleles.
    evidence:
    - reference: PMID:36740977
      reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Consistent with patients, THD iPSC-DAn displayed lower levels of DA
        metabolites and reduced TH expression, when compared to controls.
      explanation: The patient-derived model recapitulates reduced TH expression.
  - target: Cerebral Catecholamine Deficiency
    description: Reduced dopamine metabolites model the central biochemical defect.
    evidence:
    - reference: PMID:36740977
      reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Consistent with patients, THD iPSC-DAn displayed lower levels of DA
        metabolites and reduced TH expression, when compared to controls.
      explanation: The model reproduces dopamine-metabolite depletion.
  findings:
  - statement: THD neurons have reduced neurite length and arborization.
    supporting_text: >-
      THD iPSC-DAn showed abnormal morphology, including reduced total neurite
      length and neurite arborization defects.
    evidence:
    - reference: PMID:36740977
      reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Moreover, THD iPSC-DAn showed abnormal morphology, including reduced
        total neurite length and neurite arborization defects, which were not
        evident in DAn differentiated from control-iPSC.
      explanation: Patient-derived neurons reveal a cellular neurodevelopmental phenotype.
  - statement: Levodopa response depends on phenotype and treatment timing in this model.
    supporting_text: >-
      L-Dopa treatment at the stage of neuronal precursors could prevent the
      alterations in THDB-iPSC-DAn.
    evidence:
    - reference: PMID:36740977
      reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Interestingly, L-Dopa treatment at the stage of neuronal precursors
        could prevent the alterations in THDB-iPSC-DAn, thus suggesting the
        existence of a critical developmental window in THD.
      explanation: The experiment supports a model-specific developmental treatment window.
  evidence:
  - reference: PMID:36740977
    reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our iPSC-based model recapitulates THD disease phenotypes and response to
      treatment, representing a promising tool for investigating pathogenic
      mechanisms, drug screening, and personalized management.
    explanation: The study validates the model for mechanistic and treatment research.
- name: BH4 stabilization assay in THD patient-derived neurons
  experimental_model_type: IPSC_DERIVED_MODEL
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: >-
    Dopaminergic neurons differentiated from iPSCs carrying homozygous R233H
    (THD-A) or compound R328W/T399M (THD-B) TH variants
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  conditions:
  - BH4 treatment
  - Untreated THD-A and THD-B neurons
  - Healthy control neurons
  publication: PMID:38196161
  description: >-
    Variant-stratified patient neurons were used to test whether the natural TH
    cofactor BH4 can act as a pharmacologic stabilizer and restore TH abundance
    and dopamine.
  modeled_mechanisms:
  - target: Biallelic TH Loss of Function
    description: BH4 tests rescue of variant-associated TH instability.
    evidence:
    - reference: PMID:38196161
      reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We report an increase in TH and dopamine levels, and an increase in the
        number of TH+ cells in control and THDA cells.
      explanation: BH4 increases TH and dopamine in the responsive cellular genotype.
  findings:
  - statement: BH4 increased TH, dopamine, and TH-positive cells in control and THD-A neurons.
    supporting_text: >-
      We report an increase in TH and dopamine levels, and an increase in the
      number of TH+ cells in control and THDA cells.
    evidence:
    - reference: PMID:38196161
      reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        We report an increase in TH and dopamine levels, and an increase in the
        number of TH+ cells in control and THDA cells.
      explanation: The patient-neuron experiment shows variant-dependent biochemical rescue.
  evidence:
  - reference: PMID:38196161
    reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In conclusion, our study demonstrates the stabilizing effects of BH4 on TH protein
      levels and function in THD neurons and mice, rescuing disease phenotypes
      and improving motor outcomes.
    explanation: The study supports BH4 as a preclinical TH-stabilization strategy.
discussions:
- discussion_id: gap_thd_genotype_guided_levodopa_dosing
  prompt: >-
    Which genotype, biochemical, and clinical markers should guide starting
    dose, titration rate, and adjunctive therapy across the TH-deficiency
    severity spectrum?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#TH biallelic pathogenic variants
  - treatments#Severity-adapted levodopa with a decarboxylase inhibitor
  rationale: >-
    The largest pediatric cohort associates second-allele variant class with
    dose requirements among p.R233H carriers, but it is single-center and
    single-ethnicity. The consensus guideline notes that available evidence is
    limited, while severe patients remain vulnerable to dyskinesia.
  evidence:
  - reference: PMID:41121981
    reference_title: "Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variant type-particularly R233H/nonsense versus R233H/missense
      significantly influences dose requirements, underscoring the value of
      genotype-guided, dynamic levodopa titration to optimize long-term outcomes.
    explanation: The cohort provides a testable genotype-dose association.
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Based on the limited evidence, practical recommendations have been
      developed to support clinical diagnosis, laboratory testing, neuroimaging,
      medical treatment, and non-medical interventions.
    explanation: The guideline explicitly characterizes the evidence base as limited.
- discussion_id: gap_thd_developmental_treatment_window
  prompt: >-
    Does treatment before symptomatic neurodevelopmental injury improve
    cognition and motor-network development in severe TH deficiency?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Infantile Catecholamine Deficiency Encephalopathy
  - experimental_models#Patient-derived THD iPSC dopaminergic neurons
  - clinical_trials#NCT03655223
  - clinical_trials#NCT05687474
  rationale: >-
    Patient-derived neurons suggest that precursor-stage levodopa can prevent
    severe-cell defects even when mature neurons respond poorly, and clinical
    consensus favors early diagnosis. The two registry studies screen newborns,
    but no disease-specific prospective early-treatment trial was identified.
  evidence:
  - reference: PMID:36740977
    reference_title: iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Interestingly, L-Dopa treatment at the stage of neuronal precursors could
      prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence
      of a critical developmental window in THD.
    explanation: The cellular model motivates prospective testing of treatment timing.
  - reference: PMID:41215497
    reference_title: "Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical experience suggests that early diagnosis and treatment initiation
      may improve the outcome.
    explanation: Clinical consensus supports early treatment while acknowledging limited evidence.
- discussion_id: gap_bh4_precision_rescue_translation
  prompt: >-
    Which TH genotypes can be stabilized by BH4 in vivo, and can clinically
    achievable exposure add benefit to levodopa without worsening adverse
    effects?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic TH Loss of Function
  - experimental_models#BH4 stabilization assay in THD patient-derived neurons
  - animal_models#Th-p.R203H knock-in mouse corresponding to human TH p.R202H/p.R233H disease nomenclature
  rationale: >-
    BH4 rescued TH abundance, dopamine, and motor phenotypes in selected
    patient-derived neurons and a knock-in mouse. The effect was
    genotype-dependent and no TH-deficiency-specific human interventional trial
    was identified, so BH4 remains preclinical for this indication.
  evidence:
  - reference: PMID:38196161
    reference_title: "Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These findings highlight the therapeutic potential of BH4 as a treatment
      option for THDA patients with specific variants and provide insights into
      the modulation of TH stability and its implications for THD management.
    explanation: The study itself frames BH4 as variant-specific therapeutic potential.
- discussion_id: gap_thd_family_diagnostic_burden
  prompt: >-
    Which care pathways and communication practices reduce diagnostic delay and
    family psychological burden across health systems?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - diagnosis#Molecular genetic testing
  - external_assertions#iNTD longitudinal patient registry
  rationale: >-
    The first focused caregiver study involved only five Serbian parents and
    found uncertainty, communication challenges, and emotional strain.
    Multinational registry work is needed to test generalizability and identify
    modifiable care-system factors.
  evidence:
  - reference: PMID:42141694
    reference_title: "Cognitive and emotional experiences of parents of children with Tyrosine Hydroxylase Deficiency during the diagnostic journey in Serbia: A preliminary study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Given the preliminary nature of this research and its geographic focus on
      Serbia, the findings are exploratory and may not generalize to other
      populations.
    explanation: The qualitative study explicitly identifies its generalizability limit.
datasets: []

📚

References & Deep Research

References

ORPHA:101150

Autosomal recessive dopa-responsive dystonia

1 finding

Orphanet defines autosomal recessive dopa-responsive dystonia as a very rare neurometabolic disorder spanning DRD to progressive infantile encephalopathy.

"A very rare neurometabolic disorder characterized by a spectrum of symptoms ranging from those seen in dopa-responsive dystonia (DRD) to progressive infantile encephalopathy."

Show evidence (1 reference)

ORPHA:101150 SUPPORT Other

"A very rare neurometabolic disorder characterized by a spectrum of symptoms ranging from those seen in dopa-responsive dystonia (DRD) to progressive infantile encephalopathy."

Orphanet definition supports the disease scope and severity spectrum.

PMID:20301610

Tyrosine Hydroxylase Deficiency.

1 finding

GeneReviews supports TH deficiency subtypes, biallelic molecular diagnosis, autosomal recessive inheritance, and levodopa management.

"GeneReviews describes TH-deficient DRD, infantile parkinsonism with motor delay, and progressive infantile encephalopathy, and states that diagnosis is established by biallelic TH pathogenic variants."

Show evidence (1 reference)

PMID:20301610 SUPPORT Other

"The diagnosis of TH deficiency is established in a proband by identification of biallelic pathogenic variants in TH by molecular genetic testing."

GeneReviews states the molecular diagnostic criterion.

PMID:41215497

Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.

1 finding

The 2025 iNTD consensus supports low CSF HVA followed by biallelic TH confirmation, levodopa/decarboxylase inhibitor as first-line treatment, careful management of severe-form dyskinesia, and multidisciplinary care.

"The diagnosis is suggested by the detection of low CSF homovanillic acid (HVA) and confirmed by identifying biallelic pathogenic variants in the TH gene."

Show evidence (1 reference)

PMID:41215497 SUPPORT Other

"The diagnosis is suggested by the detection of low CSF homovanillic acid (HVA) and confirmed by identifying biallelic pathogenic variants in the TH gene."

The current consensus states the diagnostic sequence.

PMID:20430833

Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis.

1 finding

A 36-patient study established the type A/type B clinical spectrum, the characteristic CSF metabolite pattern, and broad levodopa treatability.

Show evidence (1 reference)

PMID:20430833 SUPPORT Human Clinical

The cohort defines the characteristic CSF signature.

PMID:41121981

Phenotypic, Genotypic Characteristics, and Treatment Strategies of Pediatric Tyrosine Hydroxylase Deficiency: A Single-Center Retrospective Analysis of 51 Cases.

1 finding

The largest single-center pediatric cohort found movement disorders in 96.1%, developmental delay in 88.2%, autonomic symptoms in 51.0%, and genotype-associated levodopa dose differences.

"Movement disorders were present in 96.1% of cases, with developmental delay observed in 88.2%, and autonomic symptoms in 51.0%."

Show evidence (1 reference)

PMID:41121981 SUPPORT Human Clinical

"Movement disorders were present in 96.1% of cases, with developmental delay observed in 88.2%, and autonomic symptoms in 51.0%."

The pediatric cohort quantifies major clinical domains.

PMID:36740977

iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation.

1 finding

Patient-derived dopaminergic neurons show dopamine-metabolite depletion, reduced TH, neurite defects, phenotype-dependent levodopa rescue, and a possible developmental treatment window.

"THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls."

Show evidence (1 reference)

PMID:36740977 SUPPORT In Vitro

"THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls."

Patient-derived neurons reproduce the core biochemical defect.

PMID:38196161

Tetrahydrobiopterin (BH(4)) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model.

1 finding

BH4 increased TH and dopamine in patient-derived neurons and improved motor outcomes in a knock-in mouse, supporting a variant-dependent preclinical proteostasis strategy.

"Treatment with BH4 significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy)."

Show evidence (1 reference)

PMID:38196161 SUPPORT Model Organism

"Importantly, treatment with BH4 significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy)."

The knock-in mouse provides preclinical motor-rescue evidence.

PMID:41872043

Tyrosine Hydroxylase Deficiency Impairs TH Axonal Transport, Brain Function, and Neuronal Plasticity.

1 finding

A Th-p.R203H knock-in model supports defective TH axonal transport, altered striatal inhibitory circuitry, and compensatory plasticity without dopaminergic neuron degeneration.

"TH deficiency disrupts striatal inhibitory circuitry and triggers compensatory neuronal plasticity, without causing neuronal degeneration."

Show evidence (1 reference)

PMID:41872043 SUPPORT Model Organism

"Overall, our findings demonstrate that TH deficiency disrupts striatal inhibitory circuitry and triggers compensatory neuronal plasticity, without causing neuronal degeneration."

The model identifies a circuit-level consequence beyond transmitter depletion.

PMID:33996491

Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment.

1 finding

CSF remains the most informative compartment for monoamine-metabolite diagnosis; urinary dopamine can be normal and routine CSF monitoring does not reliably measure clinical treatment response.

"This study confirms that cerebrospinal fluid is the most informative body fluid to measure monoamine neurotransmitter metabolites when AADC or TH deficiency is suspected."

Show evidence (1 reference)

PMID:33996491 SUPPORT Human Clinical

The body-fluid study defines the diagnostic and monitoring roles of CSF.

PMID:36101825

Intermittent neurologic decompensation: An underrecognized presentation of tyrosine hydroxylase deficiency.

1 finding

Infection- or vaccination-associated episodic regression and hypotonia can occur in mild TH deficiency and may respond rapidly to levodopa/carbidopa.

"After viral infections or vaccination, she developed lethargy, worsened tremor, language, and motor regression including severe axial hypotonia."

Show evidence (1 reference)

PMID:36101825 SUPPORT Human Clinical

The case and literature review support stress-triggered decompensation.

PMID:20823027

Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.

1 finding

A 12-patient study linked severe disease and outcome to CSF HVA measures, reported hyperprolactinemia in severe cases, and described benefit from adjunctive selegiline in some patients.

"Hyperprolactinemia was found in 50% of the severe cases. Levodopa was the mainstay of treatment, and early addition of selegiline resulted in a remarkable response in some patients."

Show evidence (1 reference)

PMID:20823027 SUPPORT Human Clinical

"Hyperprolactinemia was found in 50% of the severe cases. Levodopa was the mainstay of treatment, and early addition of selegiline resulted in a remarkable response in some patients."

The cohort supports the endocrine signal and adjunctive treatment observation.

PMID:27830117

The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders.

1 finding

iNTD provides an international longitudinal registry for natural history, diagnosis, treatment, genotype-phenotype, and quality-of-life data.

"The patient registry will enable detailed analysis of the natural courses of the diseases, the diagnostic approaches and the current therapy strategies as well as the quality of life of the affected patients and possible genotype/phenotype-correlations."

Show evidence (1 reference)

PMID:27830117 SUPPORT Human Clinical

The registry publication defines the outcomes collected.

PMID:42141694

Cognitive and emotional experiences of parents of children with Tyrosine Hydroxylase Deficiency during the diagnostic journey in Serbia: A preliminary study.

1 finding

A five-parent qualitative study identifies diagnostic uncertainty, communication challenges, and substantial emotional burden while noting limited geographic generalizability.

"We conducted semi-structured interviews with five parents of children diagnosed with Tyrosine Hydroxylase Deficiency."

Show evidence (1 reference)

PMID:42141694 SUPPORT Human Clinical

"We conducted semi-structured interviews with five parents of children diagnosed with Tyrosine Hydroxylase Deficiency."

The qualitative study directly samples affected families.

PMID:34834538

Personalized Medicine to Improve Treatment of Dopa-Responsive Dystonia-A Focus on Tyrosine Hydroxylase Deficiency.

1 finding

TH deficiency impairs catecholamine and dopamine synthesis.

"The expert review states that DRD is associated with defective dopamine synthesis and that TH catalyzes the rate-limiting step in catecholamine biosynthesis."

Show evidence (1 reference)

PMID:34834538 SUPPORT Other

The expert review supports TH biochemistry and clinical heterogeneity.

PMID:9703425

A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population.

1 finding

Human mutation evidence links TH variants to autosomal recessive L-DOPA-responsive dystonia.

"The report identified homozygous TH R233H in three unrelated Dutch patients with autosomal recessive L-DOPA-responsive dystonia."

Show evidence (1 reference)

PMID:9703425 SUPPORT Human Clinical

The human family study directly links TH to recessive DRD.

PMID:30383639

Compound heterozygous mutations in the TH gene in a Chinese family with autosomal-recessive dopa-responsive dystonia: A case report.

1 finding

A Chinese case report supports TH compound heterozygosity, AR DRD symptoms, genetic diagnosis, and low-dose levodopa response.

"The abstract reports bradykinesia, dystonia, tremor, encephalopathy, compound heterozygous TH mutations, low-dose levodopa, and substantial dystonia improvement."

Show evidence (1 reference)

PMID:30383639 SUPPORT Human Clinical

The case report directly supports the TH-deficient clinical spectrum.

PMID:20301681

GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia.

1 finding

GCH1-deficient DRD is an important phenotypic differential distinguished by heterozygous GCH1 disease and usually autosomal dominant inheritance.

"The diagnosis of GTPCH1-deficient DRD is established in a proband by identification of a heterozygous pathogenic variant in GCH1 by molecular genetic testing."

Show evidence (1 reference)

PMID:20301681 SUPPORT Other

"The diagnosis of GTPCH1-deficient DRD is established in a proband by identification of a heterozygous pathogenic variant in GCH1 by molecular genetic testing."

GeneReviews states the molecular distinction from biallelic TH disease.

PMID:19172410

Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up.

1 finding

AADC deficiency has a distinct CSF signature with low HVA and 5-HIAA and elevated 3-O-methyldopa.

"In CSF all patients revealed the pattern typical of AADC with decreased concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated concentration of 3-ortho-methyldopa."

Show evidence (1 reference)

PMID:19172410 SUPPORT Human Clinical

"In CSF all patients revealed the pattern typical of AADC with decreased concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated concentration of 3-ortho-methyldopa."

The cohort supports the biochemical differential from TH deficiency.

clinicaltrials:NCT03655223

Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns

1 finding

Early Check is a broad voluntary newborn-screening implementation study whose current condition panel includes autosomal recessive Segawa syndrome.

"Early Check provides voluntary screening of newborns for a selected panel of conditions."

Show evidence (1 reference)

clinicaltrials:NCT03655223 SUPPORT Human Clinical

"Early Check provides voluntary screening of newborns for a selected panel of conditions."

The registry describes the broad newborn-screening program.

clinicaltrials:NCT05687474

Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect

1 finding

Baby Detect is a completed targeted-genomic newborn-screening program that included autosomal recessive Segawa syndrome among 126 conditions.

"Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes."

Show evidence (1 reference)

clinicaltrials:NCT05687474 SUPPORT Human Clinical

"Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes."

The registry describes the targeted genomic newborn-screening program.

Deep Research

Autosomal Recessive Dopa-Responsive Dystonia Deep Research Fallback ▸

Autosomal Recessive Dopa-Responsive Dystonia Deep Research Fallback

Provider Attempts

just research-disorder falcon Autosomal_Recessive_Dopa_Responsive_Dystonia started and wrote only the startup line before remaining silent during the bounded wait; the process was terminated with signal 15 and produced no usable research artifact.
timeout 45s just research-disorder openai Autosomal_Recessive_Dopa_Responsive_Dystonia wrote only the startup line and was terminated by the timeout with signal 15; it produced no usable research artifact.

Literature Scope Used

Because both providers failed, the curation used structured Orphanet evidence plus manually selected PubMed references focused on tyrosine hydroxylase deficiency, dopa-responsive dystonia treatment, and the TSPOAP1/RIMBP1 recessive dystonia mechanism.

Key cached sources:

ORPHA:101150 for disease definition, inheritance, European prevalence, TH/TSPOAP1 gene rows, MONDO/OMIM/xref rows, and Orphanet phenotype-frequency rows.
PMID:20301610 for GeneReviews statements on TH-deficiency clinical spectrum, biallelic TH molecular diagnosis, autosomal recessive inheritance, and levodopa treatment response.
PMID:34834538 for expert-review support that DRD reflects defective dopamine synthesis and that TH catalyzes the rate-limiting step in catecholamine biosynthesis.
PMID:9703425 for human mutation evidence linking TH variants to autosomal recessive L-DOPA-responsive dystonia.
PMID:34054692 for a genetically diagnosed DRD cohort including TH variants and long-term levodopa outcomes.
PMID:30383639 for a human AR DRD case report with TH compound heterozygosity, clinical features, molecular diagnosis, and low-dose levodopa response.
PMID:33539324 for TSPOAP1 biallelic variants, human recessive dystonia, mouse RIMBP1-loss motor findings, and in vitro synaptic release evidence.

Curation Conclusions

The core TH disease mechanism is biallelic TH pathogenic variation causing decreased tyrosine hydroxylase activity, decreased catecholamine biosynthesis, and impaired central dopamine synthesis.
The phenotype spectrum is explicitly broad: mild TH-deficient dopa-responsive dystonia, infantile parkinsonism with motor delay, and progressive infantile encephalopathy.
All Orphanet frequent phenotype rows in ORPHA:101150 were represented with exact structured-cache snippets; occasional and very rare Orphanet rows that capture the severe spectrum were also included.
Molecular genetic testing, CSF neurotransmitter-metabolite findings, and levodopa responsiveness are the main diagnostic anchors available from the cached evidence.
Levodopa with a decarboxylase inhibitor is the evidence-backed treatment anchor; the YAML binds the action to MAXO:0000058 pharmacotherapy and the therapeutic agent to CHEBI:15765 L-dopa.
TSPOAP1 was included because ORPHA:101150 lists it as a disease-causing loss-of-function gene and PMID:33539324 provides human, mouse, and in vitro support for an autosomal recessive dystonia mechanism through presynaptic active-zone dysfunction.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Biochemical Markers

Diagnosis

Prevalence

Differential Diagnoses

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Autosomal Recessive Dopa-Responsive Dystonia Deep Research Fallback

Provider Attempts

Literature Scope Used

Curation Conclusions